Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051582] (IRB)/ Ethics Committee (EC).  I will discuss this material with them and 
ensure they are fully informed regarding the Tendyne Bioprosthetic Mitral Valve System and 
the conduct of the study according to this protocol, applicable laws and regulatory 
regulations, including hospi[INVESTIGATOR_39047]/EC requirements.  
 
 
Clinical Site Name   
 
_______________________________________________                __________________________  
Site Investigator Signature       [CONTACT_1782]  
 
_______________________________________________    
Site Investigator Printed Name  

[CONTACT_766839], Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051583] Information ................................ ................................ ................................ .................  8 
1 Study Summary  ................................ ................................ ................................ .................  9 
2 Introduction  ................................ ................................ ................................ ....................  14 
2.1 Executive Summary  ................................ ................................ ................................ ..........  14 
2.2 Anatomy of the Mitral Valve  ................................ ................................ ............................  14 
2.2.1  Mitral Valve Disease Prevalence and Etiology  ................................ .......................  16 
2.2.2  Mitral Stenosis  ................................ ................................ ................................ ........  16 
2.2.3  Mitral Regurgitation  ................................ ................................ ...............................  16 
2.3 Pathophysiology of Untreated Mitral Regurgitation  ................................ ........................  18 
2.4 Treatment of Mitral Regurgitation  ................................ ................................ ...................  19 
2.4.1  Treatment Guidelines and Guideline Adherence  ................................ ...................  19 
2.4.2  Treatment Methods for Mitral Regurgitation  ................................ .......................  21 
2.4.3  Preclinical Evaluation of Percutaneous Mitral Valve Replacement  .....................  24 
2.5 Therapeutic Need  ................................ ................................ ................................ .............  26 
3 Device Description  ................................ ................................ ................................ ....... 27 
3.1 Intended Use  ................................ ................................ ................................ ....................  27 
3.2 Intended Clinical Performance  ................................ ................................ .........................  27 
3.3 Identification  ................................ ................................ ................................ ....................  27 
3.4 Design  ................................ ................................ ................................ ...............................  28 
3.4.1  Valve  ................................ ................................ ................................ ........................  28 
3.4.2  Valve Sizes and Models  ................................ ................................ ...........................  30 
3.4.3  Instrument Set  ................................ ................................ ................................ .........  32 
4 Risk -Benefit Analysis  ................................ ................................ ................................ ... 34 
4.1 Risk Analysis  ................................ ................................ ................................ .....................  34 
4.1.1  Risk Assessment  ................................ ................................ ................................ .......  34 
4.1.2  Risk Mitigation  ................................ ................................ ................................ ........  34 
4.2 Potential Benefits  ................................ ................................ ................................ .............  34 
4.3 Study Participation Associated Risks  ................................ ................................ ................  35 
5 Study Purpose  ................................ ................................ ................................ ................  36 
6 Study Design  ................................ ................................ ................................ ...................  36 
6.1 Geographies and Centers  ................................ ................................ ................................ . 36 
6.2 Duration  ................................ ................................ ................................ ............................  36 
6.3 Sample Size  ................................ ................................ ................................ .......................  37 
6.4 Eligibility Criteria  ................................ ................................ ................................ ..............  37 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 4 of 87  6.4.1  Inclusion Criteria  ................................ ................................ ................................ .... 37 
6.4.2  Exclusion Criteria  ................................ ................................ ................................ .... 37 
7 Objectives and Endpoints  ................................ ................................ ...........................  39 
7.1 Performance  ................................ ................................ ................................ .....................  39 
7.1.1  Technical Success Definition (Exit from procedure room)  ................................ .... 39 
7.1.2  Device Success Definition (at [ADDRESS_1051584] -procedural time points)  .........  [ADDRESS_1051585] iveness:  Individual Patient Success (1 -year)  ................................ .............  40 
7.3 Safety  ................................ ................................ ................................ ................................  40 
7.3.1  Primary Safety Objective  ................................ ................................ ........................  40 
7.3.2  Primary Safety Endpoints  ................................ ................................ .......................  40 
7.3.3  Seco ndary Safety Objective  ................................ ................................ .....................  40 
7.3.4  Secondary Safety Endpoints  ................................ ................................ ...................  41 
7.4 Valve System Usability  ................................ ................................ ................................ ..... 41 
7.4.1  Valve System Usability Objective  ................................ ................................ ............  41 
7.4.2 Valve System Usability Data  ................................ ................................ ...................  41 
7.5 Additional Endpoints  ................................ ................................ ................................ ........  41 
8 Analysis Plan and Sample Size Justification  ................................ ........................  42 
8.1 Sample Size  ................................ ................................ ................................ .......................  42 
8.2 Scre en Failures and Point of Enrollment  ................................ ................................ ..........  42 
8.3 Baseline Demographics, Clinical Background, and Protocol Administration  ...................  42 
8.4 Handling Study Discontinuations  ................................ ................................ .....................  43 
8.5 Evaluation of Primary Endpoints  ................................ ................................ ......................  43 
8.5.1  Primary Performance Objective  ................................ ................................ .............  43 
8.5.2  Primary Safety Objective  ................................ ................................ ........................  43 
8.5.3  Valve System Usability Objective  ................................ ................................ ............  44 
8.6 Evaluation of Secondary Endpoints  ................................ ................................ ..................  44 
9 Regulations  ................................ ................................ ................................ .....................  45 
10 Site Initiation Activities  ................................ ................................ ..............................  45 
10.1  Investigator and Site Selection  ................................ ................................ .........................  45 
10.2  Initiation Requirements  ................................ ................................ ................................ .... 45 
10.3  Site Training  ................................ ................................ ................................ ......................  46 
11 Screening and Enrollment  ................................ ................................ .........................  46 
11.1  Screening  ................................ ................................ ................................ ..........................  46 
11.2  Informed Consent  ................................ ................................ ................................ .............  46 
11.3  Vulnerable Population  ................................ ................................ ................................ ...... 47 
11.4  Enrollment  ................................ ................................ ................................ ........................  48 
12 Methods  ................................ ................................ ................................ ............................  49 
12.1  Overview ................................ ................................ ................................ ...........................  49 
12.2  Echocardiography  ................................ ................................ ................................ .............  50 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 5 of 87  12.3  Angiography  ................................ ................................ ................................ .....................  51 
12.3.1  Preoperative Cardiac Computerized Tomography (CT)  ................................ .......  51 
12.3.2  Intraoperative Angiography ................................ ................................ ...................  51 
12.4  Intraoperative Hemodynamic Measurements  ................................ ................................ . 51 
12.5  History and Physi cal Examination  ................................ ................................ ....................  52 
12.6  Clinical Status  ................................ ................................ ................................ ...................  52 
12.7  Kansas City Cardiomyopathy Questionnaire (KCCQ)  ................................ ........................  [ADDRESS_1051586] Identification  ................................ ................................ ................................ .......  60 
17.2  Central Database  ................................ ................................ ................................ ..............  60 
17.3  Electronic Case Report Forms (eCRF)  ................................ ................................ ...............  60 
17.4  Protocol Deviations  ................................ ................................ ................................ ..........  60 
17.5  Centre Noncompliance  ................................ ................................ ................................ ..... 60 
17.6  Data Processing and Management  ................................ ................................ ..................  60 
17.7  Confidentiality and Protection of Study Files  ................................ ................................ ... 61 
17.8  Monitoring  ................................ ................................ ................................ ........................  61 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 6 of 87  18 Adverse Event Reporting  ................................ ................................ ...........................  62 
18.1  Adverse Event (AE) Review and Classification  ................................ ................................ . 62 
18.2  Anticipated AEs  ................................ ................................ ................................ ................  63 
18.3  Relationship of AEs to the Device or Procedure  ................................ ..............................  63 
18.4  Seriousness of AEs  ................................ ................................ ................................ ............  63 
18.5  Device Deficiencies  ................................ ................................ ................................ ...........  64 
19 Responsibilities  ................................ ................................ ................................ .............  64 
19.1  Investigator Responsibilities  ................................ ................................ .............................  64 
19.2  Sponsor Responsibilities  ................................ ................................ ................................ ... 65 
19.3  Echocardiography Core Laboratory  ................................ ................................ ..................  65 
19.4  Computed Tomography Core Laboratory  ................................ ................................ ........  65 
19.5  Clinical Events Committee (CEC)  ................................ ................................ ......................  [ADDRESS_1051587] (DSMB)  ................................ ................................ ..... 66 
19.7  Publications Committee  ................................ ................................ ................................ ... 66 
20 Device Accoun tability  ................................ ................................ ................................ .. 67 
21 Study Closure  ................................ ................................ ................................ ..................  67 
21.1  Suspension or Early Termination ................................ ................................ ......................  67 
21.2  Routine Closeout  ................................ ................................ ................................ ..............  67 
22 Appendix A  ................................ ................................ ................................ ......................  68 
23 Appendix B, Statistical Methodologies  ................................ ................................ .. 76 
23.1  Scope of Analysis  ................................ ................................ ................................ ..............  76 
23.2  Purpose  ................................ ................................ ................................ .............................  76 
23.3  Hypotheses (HO, HA) for 30 -day mortality  ................................ ................................ ...... 76 
23.4  Calculation of Sample Size for Mortality  ................................ ................................ ..........  77 
23.5  Criteria for Termination  ................................ ................................ ................................ .... 77 
23.6  Analysis Populations  ................................ ................................ ................................ .........  78 
23.7  Calculation of Sample Size for Safety  ................................ ................................ ...............  78 
23.8  Planned Subgroup Analyses  ................................ ................................ .............................  79 
23.9  Comparison of Tendyne 1.0 Valve and Tendyne Low Profile (LP)  ................................ .... [ADDRESS_1051588] of Tables  
TABLE 1: CAUSES AND MECHANISMS OF MITRAL REGURGITATION1 ................................ ................................ ..... 17 
TABLE 2: TENDYNE MITRAL VALVE SIZES AND MODELS  ................................ ................................ ......................  31 
TABLE 3: STUDY PARTICIPATION ASSOCIATED RISKS ................................ ................................ ..........................  35 
TABLE 4: ASSESSMENTS AND DATA COLLECTION REQUIREMENTS  ................................ ................................ ....... 49 
TABLE 5 ESTIMATED MORTALITY  ................................ ................................ ................................ .....................  77 
TABLE 6 SAMPLE SIZE, 95%  CONFIDENCE INTERVAL  ................................ ................................ .........................  [ADDRESS_1051589] of Figures  
Figure 1. Human Heart Diagram  ................................ ................................ ................................ .... 14 
Figure 2.  Normal Mitral Valve Leaflets Viewed from the Left Atrium  ................................ ..........  15 
Figure 3. Long Axis View of Left Ventricle  ................................ ................................ .....................  15 
Figure 4.  The Inner Nitinol Frame  ................................ ................................ ................................ . 28 
Figure 5.  The Valve Inner  ................................ ................................ ................................ ..............  28 
Figure 6. The Outer Nitinol Frame (top view).  ................................ ................................ ..............  28 
Figure 7.  The Tendyne Mitral Valve (top view).  ................................ ................................ ...........  28 
Figure 8.  The Tendyne Mitral Valve with Braided Tether and Api[INVESTIGATOR_766787]  ................................ .... 29 
Figure 9. The Api[INVESTIGATOR_766787]  ................................ ................................ ................................ ................  29 
Figure 10.  The Tendyne Mitral Valve, with the Proud Anterior Element of Cuff on the Left. ...... 30 
Figure 11.  The Tendyne Mitral Valve in its Final Position within the Native Mitral Valve  ...........  30 
Figure 12 Tendyne Mitral Valve dimensions: AP, anterior -posterior; IC, intercommissural; and 
perimeter.  ................................ ................................ ................................ ..............................  [ADDRESS_1051590] Information  
 
Study Sponsor  / Device Manufacturer  
Tendyne Holdings, Inc.  (also doing business as Abbott  Medical ) 
A subsidiary of Abbott Vascular Inc.  
[ADDRESS_1051591]. Paul, M innesota , [ZIP_CODE]      
[LOCATION_003]  
 
 
Authorized Representative  
Abbott Medical  
The Corporate Village  
Da Vincilaan 11 Box F1  
1935 Zaventem  
Belgium  
Tel: [PHONE_13905] 11  
 
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 9 of 87  1 Study Summary  
Protocol Title  Expanded Clinical Study of Tendyne Mitral Valve System  
Investigational 
Device:  Tendyne Bioprosthetic Mitral Valve System  
Purpose:  The purpose of this expanded clinical study is to evaluate the 
performance and safety of the Tendyne Mitral Valve System in the 
treatment of severe mitral regurgitation in patents with functional 
disability greater than or equal to NYHA Class II, who are n ot suitable 
candidates for surgical replacement with otherwise available devices. 
The data gathered in this study will be used to support conformity 
requirements for CE Mark of the Tendyne Mitral Valve S ystem, using an 
appropriately powered sample size to enable assessment of the study 
safety and performance endpoints of the Tendyne Mitral Valve System 
in the intended populations.  
This study will be continued after the CE Mark to collect long -term  
safety and performance data as part of the Tendyne post -mark et follow -
up program.  All patients shall continue to be followed through [ADDRESS_1051592] -market setting . 
Design:  Nonclinical assessments, pre -clinical data, and acute clinical study data 
have been used to evaluate the Tendyne Bioprosthetic Mitral Valv e 
System design concept.  This study is required to collect further data.  
This study is a single -arm, multicenter study designed in accordance 
with the MVARC [ADDRESS_1051593] ISO 5840 -3:2013.  The 
subjects will be individuals who have symptomati c mitral valve 
regurgitation and meet eligibility criteria.  
Population:  Subjects who are 18 years or older with a symptomatic mitral valve 
regurgitation may be invited to participate in this study.  
Sample Size:  Up to 110 subjects will be enrolled into the study in support of the CE 
Mark.  Up to  an additional 2 40 subjects (for an overall sample size of 
350) may  be enrolled in the study  to evaluate the long -term 
performance of the Tendyne Mitral Valve . Refer to Section 8, Analysis 
Plan and Sample Size Justification; and Appendix  B, Statistical 
Methodology.    
Clinical Sites:  Up to [ADDRESS_1051594]/ethics committee 
and/or other approvals, be in countries in which the study has been 
approved as required by [CONTACT_2371], and  be approved by [CONTACT_766831].  Geographies being considered for the study include 
Australia, Canada, Europe,  and the [LOCATION_002].  
Objective and 
Endpoints:  Endpoints were selected to enable the sponsor, its safety committees, 
and regulator y agencies the ability to compare estimates obtained from 
this study to estimates from studies of other comparable procedures 
and devices.  Objectives and endpoints were selected based on input 
from medical advisors experienced in related procedures and st udies of 
other replacement valves and devices used to treat mitral regurgitation.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 10 of 87  Inclusion 
Criteria:  Subjects must meet ALL of the following criteria:  
1. Severe mitral regurgitation of primary or secondary etiology 
according to MVARC (Mitral Valve Academic Research 
Consortium) 2015 defined as:  
• For Degenerative MR: EROA ≥ 40 mm2 or regurgitant 
volume ≥ 60ml  
• For Secondary MR: EROA ≥ 20 mm2 or regurgitant volume ≥ 
30ml  
2. [LOCATION_001] Heart Association (NYHA) functional Class ≥ II while 
on guideline directed medical therapy (GMDT), including device 
therapy (CRT) if indicated.   
3. Heart team determines patient is not a suitable candidate for 
traditional surgical treatment accordin g to valid guidelines . 
4. Age 18 years or older.  
Exclusion 
Criteria:  Subjects will be excluded if any of the following criteria are met:  
1. Severe mitral annular calcification, severe mitral stenosis, 
valvular vegetation or mass.  
2. Left Ventricle (LV) or Left Atrium (LA) thrombus.  
3. Patient has a chest condition that prevents transapi[INVESTIGATOR_766788].  
4. Left ventricular ejection fraction (LVEF) less than 30% by 
[CONTACT_6751].  
5. Left Ventricular End Diastolic Diameter (LVEDD) > 7.0 cm.  
6. Prior surgical or interventional trea tment of mitral or aortic 
valves (e.g. valve repair or replacement, MitraClip, edge to edge 
repair, aortic balloon valvuloplasty, etc.).  
7. Any planned surgery or interventional procedure within the 
period of [ADDRESS_1051595] repair, etc.  
8. Cardiac resynchronization therapy device or implantable pulse 
generator implanted with in three months of planned implant 
procedure.  
9. Myocardial Infarction (MI) within 30 days of the planned 
implant procedure.  
10. Symptomatic, unresolved multi -vessel coronary artery disease 
(CAD) or unprotected left main coronary artery disease 
requiring stenting  or Coronary Artery By[CONTACT_137870] (CABG).  
11. Cerebrovascular accident (CVA) within six months of planned 
implant procedure.  
12. Unresolved severe symptomatic carotid stenosis (> 70% by 
[CONTACT_2207]).  
13. Cardiogenic shock or hemodynamic instability requiring 
inotrop es or mechanical support devices at the time of planned 
implant procedure.  
14. Severe tricuspid regurgitation, tricuspid valve disease requiring 
surgery or severe right ventricular dysfunction.  
15. Hypertrophic or restrictive cardiomyopathy, constrictive 
pericardi tis or any other structural heart disease causing heart 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 11 of 87  failure other than dilated cardiomyopathy of either ischemic or 
non-ischemic etiology.  
16. Any of the following:  leukopenia, acute anemia, 
thrombocytopenia, history of bleeding diathesis, or 
coagulopathy  if cannot be adequately treated.  
17. History of endocarditis within six months of planned implant 
procedure.  
18. Active systemic infection requiring antibiotic therapy.  
19. Known hypersensitivity or contraindication to procedural or 
post -procedural medications (e.g.,  contrast solution, anti -
coagulation therapy) which cannot be adequately managed 
medically or hypersensitivity to nickel or titanium.  
20. Patient is undergoing hemodialysis due to chronic renal failure.  
21. Patient has pulmonary arterial hypertension (fixed PAS 
>70mmHg).  
22. Patient has COPD and is on home oxygen.  
23. Patient refuses blood transfusions.  
24. Pregnant, lactating, or planning pregnancy within next 12 
months.  
25. Participating or planning participation in an investigational 
drug or another device study.  
26. Patient or l egal guardian unable or unwilling to give informed 
consent.  
27. Patient unable or unwilling to comply with study required 
testing and follow -up visits.  
28. Patients with non -cardiac co -morbidities that are likely to result 
in a life expectancy of less than one yea r. 
Primary Safety 
Objective:  To evaluate one month procedural and device safety of the Tendyne 
Bioprosthetic Mitral Valve System.  
Primary Safety 
Endpoints:  Device success and freedom from the following device - or procedure -
related serious adverse events (SAEs) at [ADDRESS_1051596] implant, as 
classified by [CONTACT_34164] (CEC):  
 Cardiovascular death  
 Reintervention caused by [CONTACT_766832] -related dysfunction  
 Disabling stroke  
 Myocardial infarction (MI)  
 Life-threatening bleeding  
 Major Vascular Complications  
 Renal failure requiring dialysis  
 Other device -related SAEs  
 Other procedure -related SAEs  
Stroke and MI classifications will be per the Valve Academic Resear ch 
Consortium – 2 (VARC -2).  Life -threatening bleeding classifications will 
be per the Bleeding Academic Research Consortium (BARC) consensus 
(Type 2, 3, and 5).  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 12 of 87  Secondary 
Safety 
Objective:  To evaluate long -term safety of the Tendyne Bioprosthetic Mitral Valve 
System.  
Follow -up for secondary endpoints will be continued for [ADDRESS_1051597] recent guidelines, to capture long -term data on less common or 
unanticipated adverse events, on adverse events which are time -related 
(e.g. structural deterioration, adverse effects on native valve anatomy) 
and on long -term performance.   
Secondary 
Safety 
Endpoints:  Through two years post implant:  
 Device success and,  
 No device or p rocedure related SAEs  
Primary 
Performance 
Objective:  To evaluate the performance of the Tendyne Mitral Valve System  
Endpoint definitions are derived from MVARC 2015 Guidelines.  
Technical 
Success 
Definition:  Upon Exit from procedure room, alive with the f ollowing:  
 Successful access, delivery and retrieval of the transcatheter valve 
delivery system, and  
 Deployment and correct positioning of the correctly sized valve, and  
 No need for additional emergency surgery or re -intervention 
related to the device or procedure.  
Device Success 
Definition:  At [ADDRESS_1051598] -procedural time points, alive with the following:  
 Disabling stroke free, with  
 Original intended device in place, and  
 No additional surgical or interventional procedures related to 
acce ss or the device, and  
 Intended performance of the device:  
o No Device specific adverse events, such as migration, 
embolization, fracture, hemolysis, thrombosis or endocarditis, 
and 
o Maintenance of expected hemodynamic performance (e.g., 
central mitral regurgitation (MR) < 1+; mitral valve gradient < 6 
mmHg or effective orifice area (EOA) > 1.5 cm2) and,  
o No para -device complications (left ventricular outflow tract 
(LVOT) obstruction: >20 mmHg increase in LVOT gradient vs. 
baseline; paravalvular leak (PVL) > 1+; effects on coronary 
circulation or other heart structures, e.g., erosion or need for 
permanent pacemaker implantation.  
Primary 
Effectiveness: 
Individual 
Patient 
Success  Individual patient success is defined as device success and all of the 
following at 1 -year:  
• No re -hospi[INVESTIGATOR_766789] -interventions for heart failure  
• Change in NYHA functional class  
o Improvement is defined as NYHA grade ≥ 1 compared to 
baseline  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 13 of 87  • Change in distance walked, six -minute hall walk  
o Improvement is defined as ≥ 50 meters compared to baseline  
• Change in Kansas City Cardiomyopathy Questionnaire scores  
o Improvement is defined as ≥ 10 compared to baseline  
Valve System 
Usability 
Objective:  Gather and evaluate information on the usability of the Tendyne 
Bioprosthetic Mitral Valve System.  
Valve System 
Usability Data:  Data will be implanters’ assessments of usability, especially as it relates 
to the ability to successfully deliver a nd deploy the Tendyne Mitral Valve 
in the desired anatomical location.  
Additional 
Endpoints:  • Length of ICU stay  
• Length of hospi[INVESTIGATOR_4408]  
• 30-day mortality  
• 3-month mortality  
Imaging Core 
Laboratories  SPH/UBC Cardiac CT Core Lab  
University of British Columbia, [ADDRESS_1051599],  
Vancouver, British Columbia, V6T 1Z3, Canada  
Department of Radiology ‐ St. Paul’s Hospi[INVESTIGATOR_766790]. Jonathon Leipsic [EMAIL_14641]  
[CONTACT_766882] [EMAIL_14642]  
 
[LOCATION_011]/[LOCATION_003] Echocardiography Core Lab  
Beth Israel Deaconess Medical Center,  
[ADDRESS_1051600] Floor, [LOCATION_011], MA [ZIP_CODE], [LOCATION_003]  
Michael Chaung [EMAIL_14643]  
 
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051601] -market setting . 
2.2 Anatomy of the Mitral Valve  
The mitral valve (MV) is located in the heart at the atrioventricular (AV) junction between 
the left atrium (LA) and the left ventricle (LV).  The opening and closing of the MV is 
coordinated with the cardiac cycle to regulate  the flow of blood from the lungs to the systemic 
circulation.  A properly functioning MV is open during ventricular diastole to allow 
oxygenated blood to enter the LV from the LA, and closed during ventricular systole to  
prevent backflow into the LA.  
The MV apparatus consists of the following: two leaflets, annulus, chordae tendinae, and 
papi[INVESTIGATOR_247450] ( Figure 1).  These four parts acting in concert  with the walls of the LA and 
LV are required for the normal valvular function.   
 
Figure 1. Human Heart Diagram  
The MV is also referred to as the bicuspid valve, because it consists of two leaflets: anterior 
and posterior ( Figure 2).  The posterior leaflet extends around two -thirds of the AV junction.   

Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051602] with the AV junction.  The annulus is elliptical in shape, with the 
anteroposterior dimension /septal -lateral  being shorter than the commissure -
commissure /inter -commissural  dimension.  The anterior third of the annulus consists of 
fibrous connective tissue, which is shared with the aortic valve.  The posterior two -thirds of 
the annulus consists of cardiac muscle.  The annulus is pliable  and changes shape throughout 
the cardiac cycle.  
Papi[INVESTIGATOR_247450] (PMs) are fingerlike projections from the wall of the left ventricle.  The 
chordae tendinae (CT ) are  inelastic fan -shaped cords that connect the PMs to the leaflets 
(Figure 3). 
 
Figure 3. Long Axis View of Left Ventricle  
Pathology that affects any part of the MV apparatus can lead to MV disease.  Therefore, 
understanding the normal intera ction of these parts provides the backdrop for 
understanding MV disease processes, the associated outcomes, and the currently utilized 
medical therapi[INVESTIGATOR_014].2 

Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 16 of 87  2.2.1  Mitral Valve Disease Prevalence and Etiology  
Mitral valve disease can present in two general forms: (1) a narrowing of the valve, called 
mitral stenosis and (2) valvular insufficiency, which leads to mitral regurgitation.   
2.2.2  Mitral Stenosis  
Mitral stenosis (MS) is less prevalent than mitral regurgitat ion (MR).  In MS, the narrowing 
of the mitral valve is the result of the post -inflammatory changes to the leaflets, which 
become thickened, nodular, and fused at the commissures.  These leaflet changes can be 
accompanied by [CONTACT_766833] s of the PMs.  These changes typi[INVESTIGATOR_766791].  Fusion 
of the leaflets results in a funnel -shaped orifice.  Restricted leaflet motion during both diastole 
and systole may result.  This differs from secondary MR, in which the restricted leaflet motion 
normally only occurs during systole.3 
The primary cause of MS is rheumatic fever.  Although rheumatic fever is common in 
developi[INVESTIGATOR_14696], it is comparably rare in developed countr ies due to the use of 
antibiotics for streptococcal infections.  In a study of school -age children, there was a 12 -fold 
higher prevalence of rheumatic fever in developi[INVESTIGATOR_766792].3  Thus, 
MS is also less prevalent in developed countries.  In the Euro Heart Survey, which reviewed 
valvular heart disease across 25 European countries, only 27% of those patients who 
presented with  isolated MV disease had MS.  In 85% of the MS patients, the primary cause 
was rheumatic fever.  Primary etiology accounted for most of the remaining MS cases,4 with 
the majority being older (>50 years of age).  Similarly, Nkomo et al., in study of the ge neral 
population in the US found that MS occurred in 0.1% of all people with a slight increase to 
0.2% in persons ≥65 years of age.5 
As noted, MR is the more prevalent form of isolated MV disease and will be the focus of the 
remainder of this overview.   
2.2.3  Mitral Regurgitation  
[IP_ADDRESS]  Prevalence  
Two population -based studies in the US showed that mitral regurgitation (MR) is the most 
common heart  valve disease.5,6  The Framingham Offspring Study used color Doppler 
echocardiography to assess for MR , which  was detected in 90% of the subjects, albeit trace 
or mild in severity (not clinically significant) in the majority of cases.  However, 1.6% of 
subjects had moderat e to severe MR.[ADDRESS_1051603] common factors associated with the 
presence of MR were older age, lower body mass index, heart failure, myocardial infa rction 
(MI) and hypertension.   
Similarly, a population -based study by [CONTACT_766834]. found moderate to severe MR occurring 
in approximately 1.7% of the US population with increasing prevalence among older 
individuals (7.3% of those ≥65 years of age).   The authors estimated that in the year [ADDRESS_1051604] moderate valve disease to t ertiary 
centers  were included.8  This suggests that patients  with moderate or severe MR are not being 
properly refe rred for treatment, and important interventions are being delayed.  
[IP_ADDRESS]  Etiology  
There are two basic causes of MR: ischemic (e.g., subsequent to coronary artery disease) and 
nonischemic (all other causes).   
The mechanisms are broadly classified as secondary (e.g., secondary to ischemia or LV 
remodeling) or primary (e.g., intrinsic valve lesions).  The mechanisms can be further 
subdivided based on Carpentier’s functional types, which describe leaflet motion in relation 
to the mitral annular plane: 9 
• Type I.  Normal leaflet motion.  MR is due to leaflet perforation or annular dilatation, 
which is usually the result of LV disease.  
• Type II.  Excessive leaflet motion above the annular plane (leaflet prolapsed) into the 
LA. 
• Type III.  Restricted leaflet m otion.  
o Type IIIa.  Restricted leaflet movement throughout the cardiac cycle (both 
systole and diastole).  
o Type IIIb.  Restricted leaflet movement in systole alone.  
The causes and mechanisms of MR are s ummarized, as follows, in Table 1. 
Table 1: Causes and Mechanisms of Mitral Regurgitation1 
CAUSE  MECHANISM  
Primary  Secondary  
Type I  Type II  Type IIIa  Type I/Type IIIb  
Non -
ischemic  • Endocarditis 
(perforation)  
• Degenerative 
(annular 
calcification)  
• Congenital 
(cleft leaflet)  • Degenerative 
(billowing/flail 
leaflets)  
• Endocarditis 
(ruptured CT)  
• Traumatic 
(ruptured CT/PM)  
• Rheumatic (acute 
RF) • Rheumatic (chronic RF)  
• Iatrogenic 
(radiation/drug)  
• Inflammatory 
(anticardiolipin/  
eosinohilic endocardial 
disease/lupus/  
endomyocardial 
fibrosis)  • Cardiomyopathy  
• Myocarditis  
• LV dysfunction 
(any cause)  
Ischemic   • Ruptured PM   • Functional 
ischemic  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051605] common etiologies for patients requiring surgical correction 
are primary (myxomatous), ischemic, rheumatic, and endocarditis.1,7,[ADDRESS_1051606]  common 
form of primary MR being MV prolapse.  Prolapse can be moderate, with leaflet edges 
remaining in the ventricle; or severe, with eversion of the leaflets, usually the posterior 
leaflet, into the LA.  This severe eversion of the leaflets, also called  flail leaflets, is usually the 
result of ruptured CT.  A less common form of primary MR is calcification of the annulus.   
Secondary MR accounts for approximately 20 to 25% of surgical correction cases.  Secondary 
MR may result from annular enlargement se condary to LV dilatation or PM displacement due 
to LV remodeling.[ADDRESS_1051607] resulting in tethered and api[INVESTIGATOR_766793].  Changes in the 
annulus and the tethering of the leaflets, either alone or together, results in loss of coaptation 
that yields secondary MR.  
2.3 Pathophysiology of Untreated Mitral Regurgitation  
The pathophysiology of the disease is variable depending on the mechanism of MR. In 
significant primary MR, there is a volume overload of the left ventricle that results in LV 
hypertrophy to compensate for both the metabolic demands of the body (forward stroke 
volume) and regurgitant volume with each heartbeat.  There is also a compensatory gradual 
enlargement  of the LA and increase in LA compliance.  This increased LA compliance allows 
for near normal drainage from the pulmonary veins.  This is the chronic, compensated phase 
of the disease during which patients may be asymptomatic and have normal exercise 
tolerances .   
Compensated MR may persist for many years.  At some point, however, the LV myocardium 
is no longer able to contract adequately to overcome the volume overload caused by [CONTACT_66243]. The 
reduced ability of the LV to contract results in a decreased stroke volume, whi ch leads to 
decreased cardiac output, an increase in end systolic volume, increased LV filling pressures 
and increased pulmonary congestion.  In this stage, the patient displays signs of heart failure 
and exercise intolerance.  In an attempt to increase ca rdiac output, there is further dilatation 
of the LV, which leads to increasing dilatation of the MV annulus and increasingly more severe 
MR.  An additional complicating feature is that LA enlargement predisposes patients to AF 
and arterial thromboembolism.   Left untreated, patients may develop pulmonary 
hypertension and right -sided heart failure.[ADDRESS_1051608] to clinical status 
or mortality.  Approximately 50% of patients with primary MR have a normal life 
expectancy.11 At the other end of the spectrum, 20% are at high risk for progression to heart 
failure or death without surgical corr ection.  The predictors of this more severe course 
include moderate and severe MR and reduction in ejection fraction.[ADDRESS_1051609] -MI.  In this population, MR was present in 50% with 12% being categorized as 
moderate/ severe.[ADDRESS_1051610] of 
secondary MR on heart chamber remodeling, clinical evidence strongly indicates that in 
patients with LV dysfunction, secondary MR worsens the prognosis.12,13,14,15,16  Grigioni et al. 
showed that patients with ischemic MR (IMR) had a significantly higher all -cause mortality 
and cardiac mortality incidence at 5 years when compared to a cohort of patients with 
ischemic heart disease and no MR.12  Their work further showed that revascularization 
therapy alone did not eliminate the poor prognosis for patients with MR.  A subgroup analysis 
of patients in the CADILLAC  trial showed that MR was strongly associated with 30 day and 1 
year mortality patients undergoing percutaneous coronary intervention procedures for acute 
MI.12 More severe MR was associated with a higher mortality rates (1.4%, 3.7%, and 8.6% at 
30 days; 2.9%, 8.5%, 20.8% at 1 year for no, mild, and moderate/severe MR, respectively).  
DeServi et al. reported similar results in a younger patient cohort experiencing a first MI.15  
In this study, the 15 -month mortality for patients with IMR was more than three times that 
of patients w ithout IMR (9.8% versus 3.2%).  Furthermore, patients with IMR were more 
likely to develop heart failure at 15 months (20% versus 3%).   
Even though IMR is a strong predictor of poor outcomes following revascularization 
procedures, there are no guidelines for patient follow -up.[ADDRESS_1051611] that there is a substantial population of patients that could benefit from correction of 
IMR, which could lead to improved outcomes.  
2.4 Treatment of Mitral Regurgitation  
2.4.1  Treatment Guidelines and Guideline Adherence  
The American C ollege of Cardiology/American Heart Association (ACC/AHA) and the 
European Society of Cardiology/European Association for Cardio -Thoracic Surgery 
(ESC/EACTS) have published guidelines for the management of valvular heart disease.17,18  In 
summary, the guid elines  contain the following Class I  recommend ations.   
Primary MR  
• Symptomatic patients with severe primary MR and without severe LV dysfunction  
• Asymptomatic patients with severe primary MR and LV dysfunction  
• Repair is preferable to replacement when a suc cessful and durable repair can be 
accomplished  
• Patients with chronic severe primary MR undergoing cardiac surgery for other 
indications (ACC/AHA Guidelines only)  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 20 of 87  Secondary MR  
• Patients with severe MR undergoing CABG and without severe LV dysfunction 
(ESC/EA CTS only – there are no Class I recommendations for surgical intervention in 
the ACC/AHA Guidelines)  
Despi[INVESTIGATOR_766794] -defined guidelines and the abundant literature that indicates 
that the 10 year survival rate for medically managed patients r anges from 20 to 
60%19,20,21,22,23,  several studies have shown that guideline adherence is poor, and many 
patients go without recommended treatment.24,25,26,27  An evaluation of surgical interventions 
in the Euro Heart Survey showed that only 193 of 396 (48.7%) of patients with severe 
sympt omatic MR had a surgical valve procedure.  Multivariate analysis identified five factors 
that led to the decision not to operate: LV dysfunction, non -ischemic etiology, patient age, 
comorbidities, and grade 3 versus more severe grades of MR.  Specifically,  these data showed 
that patients with LVEF between 30 and 60% accounted for 53% of the population that did 
not receive surgery, despi[INVESTIGATOR_766795] o f LV dysfunction being a C lass I recommendation in 
both the ACC/AHA and ESC/EACTS guidelines.26  Similarly, Bach et al. evaluated 300 patients 
identified in the University of Michigan database with significant MR.  Of these patients, 112 
had primary MR, but mitral surgery was performed on only 59 (53%) of the patients.  Of the 
patients who did not undergo surgical intervention, 39/53 (74%) met the guideline 
requirements for MV surgery.24  Toledano et al. published on the results of a questionnaire 
mailed to all cardiologists in Canada to identify causes of non -compliance to the published 
guidelines.  They found that only 57% of respondin g cardiologists correctly identified that an 
LVEF of 50 to 60% should trigger a referral for surgery.  Further, only 16%  would correctly 
refer an NYHA C lass II patient with severe MR and an LVEF >60%.27  
To evaluate longitudinal outcomes of isolated MV repair in older patients, Badhwar et al. 
performed an analysis of linked data from the Society of Thoracic Surgeons (STS) adult 
cardiac surgery datab ase and claims data from the Centers for Medicare & Medicaid Service 
(CMS) covering a period from [ADDRESS_1051612] a worse prognosis than patients with MR from other causes.  The 
general belief has been that early reperfusion with percutaneous coronary intervention (PCI) 
or coronary artery by[CONTACT_250534] (CABG) would reduce ischemic damage to the heart muscle 
and retard the process of LV remodeling, thereby [CONTACT_766835].[ADDRESS_1051613] that 
MV repair or reduction of annular diameter with an annuloplasty ring concomitant with a 
CABG procedure may provide benefit.35,36,37,38  It should be noted ; however , that  surgical 
treatment of  secondary MR is evolving such that many patients will not receive repair or 
replacement unless the patient has concomitant surgical indications for revascularization  or 
aortic valve replacement . 
2.4.[ADDRESS_1051614] been used for 
many years.  Percutaneous methods are currently being developed and beco ming 
increasingly more available.   
[IP_ADDRESS]  Surgical Repair  
Surgical repair for primary mitral valves can be traced to the technique developed by 
[CONTACT_296535], the “French correction”, which involved quadrangular resection of prolapsed 
leaflets, transposition of nor mal chords to other areas of the leaflet, as needed, and utilization 
of a ring annulus as part of a remodeling annuloplasty.[ADDRESS_1051615] “saddle -shaped” structure and 
flexibility of the mitral annulus.  There are no conclus ive data to suggest that these alternative 
ring forms enhance long -term clinical benefit.39,40,41,[ADDRESS_1051616] -MV repair  follow -up, freedom from reoperation was 96±2%, 
88±4%, and 94±2% ( p=0.019) for posterior, anterior and bileaflet prolapse, respectively.  
Freedom from >2+ MR at [ADDRESS_1051617] introduc ed by [CONTACT_296535]:  artificial chordae and edge -to-edge approximation.   
The artificial chordae technique replaces diseased chordae without the chord transposition 
or resection that was introduced as part of the Carpentier method.46  However Salvador et al.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 22 of 87  published 15 -year follow -up data on 608 patients who had MV repair with artificial chordae.  
These patients had an 84% survival rate, 92% freedom from reoperation, and 85% freedom 
from severe MR.[ADDRESS_1051618] been suboptimal.  Edge -to-edge repair has, however, 
improved outcomes of patients with anterior l eaflet prolapse.  A single -cent er study 
compared 133 patients undergoing edge -to-edge repair of anterior leaﬂet prolapse and 605 
patients undergoing quadrangular resection of the posterior leaﬂet with or without 
annuloplasty.  Over the follow -up period (mean 4.5±3.1 years), freedom from reoperation in 
the anterior group was not inferior (96±2% in the anterior leaﬂet prolapse group versus 
97±1% in the posterior leaﬂet prolapse group, p=0.37).49 
[IP_ADDRESS]  Surgical Replacement  
There are conditions where the valve is not amenable to repair including prolapsed leaflets 
associated with extensive annular calcification, prolapse of one leaflet with hypoplasia of the 
opposite leaflet, extreme fibroelastic deficiency, and extensive postendocarditis tissue 
destruction.[ADDRESS_1051619] viable treatment option.  There are 
two basic types of prosthetic valves: mechanical prostheses and bioprostheses.  Mechanical 
prostheses require lifelong anticoagulation therapy but have  longer durability, whereas 
bioprostheses do not req uire long -term anticoagulation but are subject to structural valve 
deterioration (SVD) over time.  A 20 -year follow -up of 1285 patients with MV bioprostheses 
determined the estimated freedom from SVD at 5, 10, and 15 years to be 98±1%, 69±2, and 
32±4%, res pectively.51  The choice of which type of valve prosthesis to use is largely related 
to patient life expectancy and risk of developi[INVESTIGATOR_21377] -related bleeding and 
thromboembolism.   
The ESC/EACTS C lass I recommendations for mechanical prostheses inc lude patients that 
have no contraindications for long -term anticoagulation, who are at increased risk for 
accelerated SVD (<40 years of age or hyperparathyroidism), or are already on 
anticoagulation due to a mechanical v alve in another location.  The C lass IIa 
recommendations include patients <65 years of age and/or those who have a reasonable life 
expectancy and for whom a reoperation would be contraindicated because of patient risk.   
The ESC/EACTS C lass I recommendations for bioprostheses include patient s with a high risk 
of bleeding or those that are having a reoperation for mec hanical valve thrombosis.  The C lass 
IIa recommendations include patients who are at low risk of future valve reoperation or are 
>70 years of age.52 
[IP_ADDRESS]  Comparison of Surgical Treatme nt Interventions  
 The Euro Heart Survey, which was conducted from April to July 2001, showed that the 
number of patients undergoing MV replacement versus repair were similar.  Of 155 patients 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 23 of 87  who underwent surgery for MR, slightly more than half (83/155) h ad a valve replacement, 
with the majority being mechanical prostheses (67/83).  O’Brien et al. showed similar trends 
using the Society of Thoracic Surgeons (STS) database for the period covering the years 2002 
to 2006.  Over 40,000 patients undergoing MV s urgery were evenly divided between isolated 
MV replacement (21,229) and isolated MV repair (21,238).[ADDRESS_1051620] come 
into wider use to make surgical correction, rather than replacemen t, a viable option for 
increasingly greater numbers of patients. However,  MV repair surgery tends to be more 
com plex, requiring a surgical center  that is experienced with repair techniques.  The re are a 
limited number of centers  with the necessary expertis e.   
Despi[INVESTIGATOR_766796], the published guidelines for the management of valvular heart 
disease currently specify MV repair as the surgical intervention of choice .52,54  The 
recommendation is based largely on data that show a lower risk associated with MV repair 
over MV replacement.  Evidence suggests that repair is effective and is associated with 
reduce d morbidity and mortality compared to replacement.18,54  In the STS risk model for 
valvular surgery, patients with valve replacements were more than three times more likely 
to die within 30 days of the surgery (5.7% to 1.6%), and more than twice as likely to 
experience the one or more major morbidity or mora lity events (26.7% to 12.7%).[ADDRESS_1051621] a negative influence 
on outcomes.56,57,58,59 The apparent superiority of MV repair over replacement did not hold 
up to propensity matching analysis, which found no significant difference in mortality (at 5, 
10, and 15 years) nor in freedom from reoperation (at 5 and 10 years) between repair and 
repl acement.55  
Until recently, there has been a lack of randomized controlled data comparing repair and 
replacement.  However, a recent report by [CONTACT_766836]. of a randomized controlled trial that 
compared  repair versus replacement in 251 patients with severe IMR showed that 
replacement had similar or better outcomes than repair.60  Specifically, there was no 
significant difference in 12 -month mortality (14.3% for repair versus 17.6% for replacement) 
or cha nge in LVESV index from baseline ( -6.6 mL/m2 for repair versus -6.8 mL/m2 for 
replacement). In fact the rate of recurrence of moderate or severe MR was significantly 
greater in the repair group (32.6% versus 2.3%, p<0.001).  The authors concluded that 
“rep lacement provided a more durable correction of mitral regurgitation.”60  
Surgical interventions for MR are underutilized within the context of exis ting 
guidelines.24,25,26,27  An important goal in addressing the growing problem of MR is to raise 
awareness such that patients who would benefit from either MV repair or replacement are 
referred in a timely manner.   
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 24 of 87  [IP_ADDRESS]  Percutaneous Mitral Valve Repair  
Many MR patients, however, are n ot good surgical candidates.  Age and comorbidities may 
make them unsuitable for anesthesia and open -heart surgery with cardiopulmonary by[CONTACT_6476].  
With the aim of providing lower -risk therapi[INVESTIGATOR_766797], treatments throug h percutaneous methods are being developed.   
Percutaneous  devices for MV repair have been evaluated in clinical trials and reported in 
peer -reviewed literature.  One such device, MitraClip, is based on the edge -to-edge 
technique.61,62,63,64,65,66,67,68,[ADDRESS_1051622] MV repair surgery63,66 and in several registry studies.63,64,65,66,67,68,69  In the randomized 
controlled trial, the MitraClip patients fared worse on the 12 -month  primary endpoint of 
freedom from death, surgery for MV dysfunction, and MR grade 3+ or 4+ than did the patients 
undergoing MV repair su rgery (55% to 73%; p=0.007).[ADDRESS_1051623] a favorable risk -benefit profile is inconclusive , 
larger scale clinical studies and randomized contr olled trials are required to further evaluate 
them.70,71,72 
[IP_ADDRESS]  Percutaneous Mitral Valve Replacement  
Transcatheter aortic valve replacement (TAVR) has become a therapeutic option for high risk 
and extreme surgical risk patients with symptomatic calcif ic aortic stenosis73 and is now 
being studied for intermediate risk, failed bioprosthetic valves, bicuspid aortic stenosis and 
aortic insufficiency.  Several valves for TAVR are commercially available  in Europe and The 
[LOCATION_002] and more newly designed  valves undergoing development.[ADDRESS_1051624] for transcatheter 
mitral valve replacements, but the mitral valve has been a much more elusive target.  
Transcatheter mitral valve replacement (TMVR) faces challenges arising from not  only the 
heterogeneity of mitral valve pathology but also from its complete intracardiac positioning.  
The mitral annulus, leaflets and subvalvular apparatus offer significant obstacles to valve 
delivery.[ADDRESS_1051625] emerged in recent years.  
2.4.3  Preclinical Evaluation of Percutaneous Mitral Valve Replacement  
Development and preclinical evaluation of candidate devices for MV replacement has focused 
in two gener al areas: devices that can be stably implanted within the native mitral valve 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 25 of 87  apparatus and devices that can be implanted within valves or rings that were surgically 
implanted in previous procedures (e.g., valve -in-valve).   
The first literature reports of  off-pump, percutaneous MV valves were in 2005 by [CONTACT_766837]. 
and Boudjemline et al.75,76  Ma et al. utilized a “double -crown” stented valve.  This valve was 
implanted at the mitral location through the transatrial route and centered on the mitral 
annulus th at was previously marked with clips.  
The Lutter group has performed the most extensive series of transapi[INVESTIGATOR_766798].73,77 ,78,79,80,81,82  Early device prototypes utilized self -expanding 
stent with a star -shaped atrial element that was designed to prevent migration into the left 
ventricle, and ventricular fix ation system consisting of four individual neo -chordae attached 
to the ventricular rim of the stent  .  This group reported on four acute/short term studies on 
variations of the star -shaped prototype.76,77,78,79,[ADDRESS_1051626] published clinical use of a TMVR was the acute implantation of a Tendyne Mitral 
Valve . Two patients were treated under clinical protoc ol prior to receiving surgical mitral 
valve replacement .91  They reported safe implantation and reduction of severe MR with 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 26 of 87  immediat e improvement in hemodynamics.  In-hospi[INVESTIGATOR_766799].   
Implantation was safe resulting in elimination of severe MR in 2 of 3 patients (with trivial PV 
leak in the third) and all patien ts being discharged to their own home .[ADDRESS_1051627] limited life expectancy.  Cheung and Al -Lawati reported encouraging data on 36 patients 
who underwent transcatheter mitral valve -in-valve implantation.  Thirty -day mortality was 
7.5%, and surviving patients had a decrease in MR severity from 3+ and 4+ to 1+ or 0. [ADDRESS_1051628] line treatment option 
for many patients.  Additionally, there is a large patient population that has limited treatment 
options.  Specific populations of patients  with limited options include those who are not 
suitable surgical candidates, because they considered high risk for peri -procedural morbidity 
and mortality and those with secondary MR.   
These populations could benefit from a less invasive approach that do es not require an open -
heart procedure nor cardiopulmonary by[CONTACT_6476].  Therefore, transcatheter mitral valve 
implantation has the potential to be a  viable alternative to traditional mitral valve  surgery.   
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 27 of 87  3 Device Description  
3.1 Intended Use  
The Tendyne Bioprosthetic Mitral Valve System is intended for transapi[INVESTIGATOR_2855], beating heart, 
mitral valve replacement in patients with a diseased, damaged, or malfunctioning mitral 
valve.   
The Tendyne Mitral Valve  is implanted through the apex of the left ve ntricle via a left mini -
thoracotomy while the heart remains beating.  Compared to open -heart valve replacement 
surgery, access is less invasive and the risks of cardiopulmonary by[CONTACT_766838].  Thus , 
the Tendyne Mitral Valve System is designed to provi de a mitral valve replacement 
alternative for patients who are not suitable candidates for surgical 
replacement /transcatheter valve repair .   
Implantation of the Tendyne Mitral Valve  does not involve concomitant surgical removal or 
revision of the failed n ative mitral valve.  It is implanted within the native mitral valve, using 
minimally invasive techniques, such that the mitral apparatus is preserved.  Preservation of 
the native structures has been shown to improve clinical outcomes in mitral valve 
replac ement17,  as they are essential for maintaining normal left ventricular shape, volume 
and function.  
The Tendyne Mitral Valve  can be repositioned and/or retrieved intraoperatively.  These 
features are designed to allow optimization of the valve position following deployment and 
use of an alternative valve size if the initial valve does not have adequate performance.  
3.2 Intended Cl inical Performance  
The Tendyne Mitral Valve  is intended to reduce mitral regurgitation.  Reduced mitral 
regurgitation may lead to favorable left ventricular remodeling, improved quality  of life, 
fewer patient symptoms, and/or reduced hospi[INVESTIGATOR_104732].  
3.3 Identification  
The Tendyne Bioprosthetic Mitral Valve System consists of the Tendyne Mitral Valve  and an 
instrument set to facilitate placement of the valve.   
The Tendyne Mitral Valve S ystem is manufactured by [CONTACT_766839], Inc , a subsi diary of 
Abbott Vascular Inc. (also doing business as Abbott Medical) .    
The Tendyne Mitral Valve  is supplied in a 0.6% solution of glutaraldehyde for sterile 
packaging and preservation of porcine tissue components.  The instrument set is supplied 
sterile  and for single use only .   
The Tendyne Mitral Valve  is available in several sizes  to accommodate differing cardiac 
anatomies.  Each valve size is described by [CONTACT_213366] ( AP, anterior -posterior ) and minor ( ICD, 
inter -commissural dimension ) dimensions , see S ection 3.4.1  for more information . 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 28 of 87  3.4 Design  
3.4.1  Valve  
The Tendyne Mitral Valve  has three porcine pericardial tissue leaflets sewn onto a circular 
frame that is referred to as the valve inner.  The inner frame is made from nitinol, a nickel -
titanium alloy that has self -expanding properties and is radiopaque.  See Figure 4 and Figure 
5. 
 
   
Figure 4.  The Inner N itinol Frame   
Figure 5.  The Valve I nner   
 
The porcine pericardial  tissue is cross -linked before being sutured to the inner and outer 
frames .   
The valve inner is sutured to an outer nitinol frame that is covered in porcine pericardium 
with a PET (polyethylene terephthalate) fabric cuff that provides the sealing surface within 
the native annulus.  See Figure 6 and Figure 7. 
 
 
Figure 6. The Outer Nitinol Frame (top 
view).   
Figure 7.  The Tendyne Mitral Valve  
(top view).  

Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051629] tension and optimize the position of the valve within 
the mitral annulus. The api[INVESTIGATOR_766800] a PEEK (polyether ether ketone) button covered in PET 
fabric, designed to promote ingrowth.  See Figure [ADDRESS_1051630] paravalvular leak.  Figure 11 shows the Tendyne Mitral Valve  as 
intended for permanent placement.  The tether connects the valve to the apex of the ventricle 
where it is fastened by [CONTACT_599483][INVESTIGATOR_766801].   
 
Figure 10.  The Tendyne Mitral Valve, 
with the Proud Anterior Element of Cuff 
on the L eft. 
 
Figure 11.  The Tendyne Mitral Valve in 
its Final P osition within the Native 
Mitral V alve  
3.4.2  Valve Sizes and Models  
The Tendyne Mitral Valve is available in several sizes to accommodate differing cardiac 
anatomies.  Available valve sizes and models are shown in Table 2 below.   
Each valve size is described by [CONTACT_346042] -posterior  (AP) and inter -commissural (IC) 
dimensions. Imaging techniques are used by [CONTACT_766840]’s mitral valve dimensions. The valve size is chosen to provide the proper 
fit for paravalvular sealing and device stability.  
The inner valve sizes for all valve numbers are the same: The Tendyne 1.0 valve  has an EOA 
of 3.2cm2 and the low profile or LP  valve has an EOA of 2.0cm2.  

Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 31 of 87  Table 2: Tendyne Mitral Valve  sizes and models   
Valve 
Number  AP  
(mm)  IC  
(mm)  Perimeter 
(mm)  
01 32.5  34.5  113  
02 32.5  37.5  118  
03 32.5  40.5  124  
    04**  32.5  43.5  130  
05 32.5  46.5  136  
09 34.5  45.5  138  
10 34.5  48.5  144  
    14**  36.5  46.5  144  
15 36.5  49.5  150  
19 38.5  47.5  150  
20 38.5  50.5  156  
23 40.5  47.5  154  
24 32.5  50.5  144  
25 34.5  51.5  150  
26 36.5  52.5  156  
  27* 29.0  42.5  119  
*    Size available in LP only  
**   Size available in standard profile and LP  
 
Figure 12 Tendyne Mitral Valve  dimensions: AP, anterior -posterior ; IC, 
intercommissural; and perimeter.  
 
 AP dimension  IC dimension  Perimeter  
The Tendyne 1.0 valve  was introduced in clinical trials in the year 2014. During these trials  
it was recognized that a pproximately 20 -30%  of clinically suitable candidates were excluded 
from the study due to anatomical limitations, in particular the potential left ventricular 
outflow tract (LVOT) produced by [CONTACT_766841].    

Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 32 of 87  
The Tendyne LP valve  was introduced in to the clinical investigation in mid -2016 (protocol 
Rev 5.0 and higher). The LP d esign was created to potentially allow implantation in subjects 
with small ventricles where the Tendyne 1.0 valve could result in LVOT obstructions. These 
subjects typi[INVESTIGATOR_766802] e primary MR. This valve has already passed the early feasibility stage, 
with more than 20 implantations in patients.  
The differences between the Tendyne 1.0 valve  and the LP valve are described in the 
following figure.  
Figure 13.  Valve Design Differences Between Tendyne 1.0 Valve  and  LP 
 
 
 
 
 
 
 
 
 
 
The assessment of patient suitability for Tendyne Mitral Valve  treatment and the decision to 
implant the Tendyne 1.0 valve  or the LP valve  is based on 3D modeling of the LVOT created 
by [CONTACT_766842]. All assessments are carried out by [CONTACT_766843] (see 
protocol Section 19.3 ). 
Typi[INVESTIGATOR_766803]/or subjects with smaller ventricles.  
3.4.3  Instrument Set  
The instrument set included in the Tendy ne Mitral Valve System  includes (1) an access 
system that can be configured multiple ways and (2) an api[INVESTIGATOR_766804].   
The instrument sets are identical for the two  valve models.  
[IP_ADDRESS]  Access System  
The access system is designed to facilitate Tendyne Mitral Valve  implantation using standard 
transapi[INVESTIGATOR_766805].  The system is designed to facilitate gradual, controlled 
deployment of the valve and proper seating within the mitral annulus.  It is also designed to 
facilitate intraoperative repositioning, if necessary, to achieve optimal orientation within the 
annulus.  The system allows intraoperative retrieval, if necessary, to pull the valve out.  An 
alternate Tendyne Mitral Valve  may then be impl anted.  Decreased area of the leaflets 
from ES0526 -xxx resulting in a 
smaller diameter of the inner 
valve frame on ES1066 -xx. Decreased height of the valve 
outer sealing frame on ES1066 -
xx (also referred to as sealing 
height) as compared to 
ES0526 -xx of the same size.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 33 of 87  The access system includes instrumentation that may be configured for alignment, loading, 
delivery, repositioning , or retrieval .  The access system has the following features:   
• Precise alignment guide and needle access  
• Mechanisms to ensure device d oes not traverse in between chordae tendinae or 
leaflet cusps preventing future device entanglement  
• Consistent, controlled manner to collapse the implant prior to delivery  
• Atraumatic radiopaque tip introducer with dilator  
• Mechanism for controlled advanceme nt and retraction of the valve  
• Fine -positioning mechanism for precise deployment and capture of the valve  
• Flush ports for removing air from the system  
• Graduated retrieval dilator system to ensure proper collapse of the device prior to 
retrieval  
• Ability to release the pad locking mechanism if previously deployed and adjustments 
to positioning are necessary  
The access system is identical for the two valve models.  
 
[IP_ADDRESS]  Api[INVESTIGATOR_766806], at the epi[INVESTIGATOR_766807].  It has an articulating head to facilitate proper angulation, and a cam rotator that 
drives a pin through the braided tether.  The cam rotator allows for unlocking and relocking 
of the pin in case the tether tension needs  to be adjusted.  
The api[INVESTIGATOR_766808].  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051631] devices are traditionally attached 
at the apex.  Nevertheless, puncture of the left ventricular apex and subsequent closure may 
cause bruising and scar tissue, with the potential for impaired cardiac function.  The apex, 
however, contributes minimally to the overall ventricular contraction.  Damage at the apex is 
mitigated by a relatively low -profile delivery system to make the puncture as small as 
possible.   
The residual risks are disclosed in the labeling of the device (IFU) and are counterbalanced 
by [CONTACT_766844], as discussed in 
Section 4.2.   
The mini -thoracotomy required for api[INVESTIGATOR_766809].  Therefore , the mini -thoracotomy does not 
add to the morbidity risks compared to surgical repair or replacement.  
Not all risk s may be known at this time.  To see a list of anticipa ted adverse events, please see 
Section 0. 
4.[ADDRESS_1051632], less invasive access leads to lower 
operative risk.  Second, the use of cardiopulmonary by[CONTACT_766845], including 
abnormal bleeding, acute respi[INVESTIGATOR_1505], air embolism, atelectasis, blood 
clotting, capi[INVESTIGATOR_12737], hemolysis, pancreatitis, postperfusion syndrome , renal  
dysfunctio n and neurologic deficits  in elderly, which can be substantial.  
The Risk/Benefit analysis performed in accordance with ISO [ADDRESS_1051633] the residual risk associated with the treatment.  
4.3 Study Participation Associated Risks  
The risks associated with study participation  (Table 3) are those associated with standard 
clinical diagnostic und evaluative practices procedures:  
Table 3: Study Participation Associated Risks  
Study Procedures  Risks  
History, Clinical Status, QOL 
Survey, 6 -Minute Walk & Physical 
Exam  None, Minimal  
Laboratory testing  Usual risks associated with phlebotomy  
Concomitant Medication  Physician use and risk information in accordance with 
usual clinical practice and type of medication.  
ECG  None, Minimal  
Echocardiography TTE  None, Minimal  
Echocardiography TEE  Written informed consent consistent with clinic policy  
Angiography (LV 
Ventriculogram) / 
Hemodynamics  Written informed consent consistent with clinic policy  
Computerized  tomography 
angiography (CTA)  Written informed consent consistent with clinic policy  
The obtainment of patient informed consent for study procedures determined to require 
prospective informed consent will be undertaken in accordance with the procedural 
informed consent procedures and documentation content defined by [CONTACT_284250][INVESTIGATOR_472836]. The procedures required per study protocol are consistent with standard of practice 
procedures given the indication for the associated intervention.   
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051634] ISO 5840 -3:[ADDRESS_1051635] 
symptomatic mitral valve regurgitation and meet eligibility criteria.   
6.1 Geographies and Cent ers 
Up to 110 subjects will be enrolled into the study in support of the CE Mark.  Up to an 
additional 240 subjects (for an overall sample size of 350) may be enrolled in the study to 
evaluate the long -term performance of the Tendyne Mitral Valve. Refer to Sec tion 8; and 
Appendix  B, Statistical Methodology.  
Up to [ADDRESS_1051636]/ethics committee and/or other approvals, be in 
countries in which the study has been approved as required by [CONTACT_2371], and be approved by [CONTACT_766846].  Geographies being considered for the study include Australia, Canada, 
Europe, and the [LOCATION_002].  
6.[ADDRESS_1051637] -market setting, as appropriate to cap ture long -term data 
on less common or unanticipated adverse events, on adverse events which are time -related 
(e.g. structural deterioration, adverse effects on native valve anatomy) and on long -term 
performance .  Thus , it is anticipated tha t the overall study duration will be nine years  
(including the pre-market and post -market phase) . 
6.[ADDRESS_1051638] meet ALL of the following criteria:  
1. Severe mitral regurgitation of primary or secondary etiology according to MVARC 
(Mitral Valve Academic Research Consortium) 2015 defined as:  
• For Degenerative MR: EROA ≥ 40 mm2 or regurgitant volume ≥ 60ml  
• For Secondary MR: EROA ≥ 20 mm2 or regurgitant volume ≥ 30ml  
2. [LOCATION_001] Heart Association (NYHA) functional Class ≥ II while on guideline directed 
medical therapy (GMDT), including device therapy (CRT) if indicated.   
3. Heart team determines patient is not a suitable candidate for traditional surgical 
treatment accordin g to valid guidelines . 
4. Age 18 years or older.  
6.4.2  Exclusion Criteria  
 
Subjects will be excluded if any of the following criteria are met:  
1. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or 
mass.  
2. Left Ventricle (LV) or Left Atrium (LA) thrombus.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051639] condition that prevents transapi[INVESTIGATOR_766788].  
4. Left ventricular ejection fraction (LVEF) less than 30% by [CONTACT_6751].  
5. Left Ventricular End Diastolic Diameter (LVEDD) > 7.0 cm.  
6. Prior surgical or interventional trea tment of mitral or aortic valves (e.g. valve repair 
or replacement, MitraClip, edge to edge repair, aortic balloon valvuloplasty, etc.).  
7. Any planned surgery or interventional procedure within the period of [ADDRESS_1051640] repair, etc.  
8. Cardiac resynchronization therapy device or implantable pulse generator implanted 
with in three months of planned implant procedure.  
9. Myocardial Infarction (MI) within 30 days of the planned implant procedure.  
10. Symptomatic, unresolved multi -vessel coronary artery disease (CAD) or 
unprotected left main coronary artery disease requiring stenting  or Coronary Artery 
By[CONTACT_137870] (CABG).  
11. Cerebrovascular accident (CVA) within six months of planned implant procedure.  
12. Unresolved severe symptomatic carotid stenosis (> 70% by [CONTACT_2207]).  
13. Cardiogenic shock or hemodynamic instability requiring inotrop es or mechanical 
support devices at the time of planned implant procedure.  
14. Severe tricuspid regurgitation, tricuspid valve disease requiring surgery or severe 
right ventricular dysfunction.  
15. Hypertrophic or restrictive cardiomyopathy, constrictive pericardi tis or any other 
structural heart disease causing heart failure other than dilated cardiomyopathy of 
either ischemic or non -ischemic etiology.  
16. Any of the following:  leukopenia, acute anemia, thrombocytopenia, history of 
bleeding diathesis, or coagulopathy  if cannot be adequately treated.  
17. History of endocarditis within six months of planned implant procedure.  
18. Active systemic infection requiring antibiotic therapy.  
19. Known hypersensitivity or contraindication to procedural or post -procedural 
medications (e.g., contrast solution, anti -coagulation therapy) which cannot be 
adequately managed medically or hypersensitivity to nickel or titanium.  
20. Patient is undergoing hemodialysis due to chronic renal failure.  
21. Patient has pulmonary arterial hyperten sion (fixed PAS >70mmHg).  
22. Patient has COPD and is on home oxygen.  
23. Patient refuses blood transfusions.  
24. Pregnant, lactating, or planning pregnancy within next 12 months.  
25. Participating or planning participation in an investigational drug or another device 
study. 
26. Patient or legal guardian unable or unwilling to give informed consent.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 39 of 87  27. Patient unable or unwilling to comply with study required testing and follow -up 
visits.  
28. Patients with non -cardiac co -morbidities that are likely to result in a life expectancy 
of less than one year.  
7 Objectives and Endpoints  
Endpoints  were selected to enable the sponsor, its safety committee s, and regulatory 
agencies the ability to compare estimates obtained from this study to estimates from studies 
of other comparable procedures and devices.  Objectives and endpoints were selected based 
on input from medical advisors experienced in related pr ocedures and studies of other 
replacement valves and devices used to treat mitral regurgitation.  
7.1 Performance   
Provide initial insight in to the performance of the Tendyne Mitral Valve System  by [CONTACT_766847].  
7.1.1  Technical Success Defi nition (Exit from procedure room ) 
Alive with the following:  
• Successful access, delivery and retrieval of the transcatheter valve delivery system, 
and 
• Deployment and correct positioning of the correctly sized valve, and  
• No need for additional emergency surgery or re -intervention related to the device or 
access procedure.  
7.1.2  Device Success  Definition  (at [ADDRESS_1051641] -procedural time points ) 
Alive with the following:  
• Disabling stroke free, with  
• Original intended device in place, and  
• No additi onal surgical or interventional procedures related to access or the device, 
and 
• Intended performance of the device : 
o No Device specific adverse events, such as migration, embolization, fracture, 
hemolysis, thrombosis or endocarditis, and  
o Maintenance of expe cted hemodynamic performance (e.g., central mitral 
regurgitation (MR) < 1+; mitral valve gradient < 6 mmHg or effective orifice area 
(EOA) > 1.5 cm2) and,  
o No para -device complications  (left ventricular outflow tract (LVOT) obstruction: 
>20 mmHg increase i n LVOT gradient vs. baseline; paravalvular leak (PVL) > 1+; 
effects on coronary circulation or other heart structures, e.g., erosion or need for 
permanent pacemaker implantation.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 40 of 87  7.2 Primary Effectiveness:  Individual Patient Success (1 -year)  
Individual Patien t success is defined as d evice success and all of the following :  
 No re -hospi[INVESTIGATOR_766789] -interventions for heart failure   
 Change in NYHA functional class  
o Improvement is defined as NYHA grade ≥ 1 compared to baseline  
 Change in distance walked, six-minute hall walk  
o Improvement is defined as ≥ 50 meters compared to baseline  
 Change in Kansas City Cardiomyopathy Questionnaire scores  
o Improvement is defined as ≥ 10 compared to baseline  
7.3 Safety  
Provide  insight into the safety profile of the Tendyne Mitral Valve System and procedure.  
7.3.1  Primary Safety Objective  
To evaluate one  month procedural and device safety of the Tendyne Bioprosthetic Mitral 
Valve System.  
7.3.2  Primary Safety Endpoint s  
Device success and f reedom from the following device - or procedure -related serious adverse 
events  (SAEs)  at [ADDRESS_1051642] implant , as classified by [CONTACT_34164]:  
• Cardiovascular death  
• Reintervention caused by [CONTACT_766832] -related dysfunction  
• Disabling Stroke  
• Myocardi al infarction  (MI)  
• Life-threatening bleeding  (BARC Type 2, 3, and 5)  
• Major Vascular Complications  
• Renal failure requiring dialysis  
• Other d evice -related SAEs  
• Other p rocedure -related SAEs  
Stroke and MI classifications will be per the VARC -2.  Life -threatening bleeding classifications 
will be per the Bleeding Academic Research Consortium (BARC) consensus. Criteria are 
provided in  Appendix A . 
7.3.[ADDRESS_1051643] recent guidelines, to capture long -term 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 41 of 87  data on less common or unanticipated adverse events, on adverse events which are time -
related (e.g. , structural deterioration, adverse effects on native valve anatomy ) and on long -
term performance.  
7.3.[ADDRESS_1051644] implant:  
 Device success, and  
 No device or procedure related SAEs  
 
7.4 Valve System Usability   
7.4.1  Valve System Usability  Objective  
Gather and evaluate information on the usability of the valve system.  
7.4.2  Valve System Usability  Data  
Data will be implanters’ assessments of usability, especially as it relates to the ability to 
successfully deliver and deploy the Tendyne Mitral Valve in the desired anatomical location . 
7.5 Additional Endpoints  
 Length of ICU stay  
 Length of hospi[INVESTIGATOR_4408]  
 30 day mortality  
 3-month mortality  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 42 of 87  8  Analysis Plan  and Sample Size Justification  
Descriptive statistics for each variable will be calculated which will include measures of 
central tendency, variation, a frequency histogram and a count of the number of missing 
values.  
When the arithmetic mean is found not to be an appropriate measure of central tendency, 
alternative statistics will be considered (e.g., median). When the distribution of a varia ble 
does not support the use of parametric statistics, nonparametric approaches or data  
transformations may be implemented. If data transformations are used, they will be specified  
in the final clinical report.  
The anticipated primary safety endpoint will be reported in the range of 80 to 90% (device 
success and freedom from the CEC adjudicated device - or procedure -related serious adverse 
events (SAEs) through [ADDRESS_1051645] implant.  If we conservatively estimate the scenario that 
the freedom f rom safety rate is 80%, a sample size of 94 subjects will yield precision (defined 
as distance from point estimate to lower 95% confidence limit) of 9%.  If we allow up to 15% 
attrition, a sample size of [ADDRESS_1051646] 9% provided the safety rate is 80% or better.  
8.1 Sample S ize  
Up to 110 subjects will be enrolled into the study in support of the CE Mark.  Up to an 
additional 240 subjects (for an overall sample size of 350) may be enroll ed in the study to 
evaluate the long -term performance of the Tendyne Mitral Valve. Refer to Section 8; Analysis 
Plan  and Sample Size Justification , and Appendix  B, Statistical Methodology.  
8.[ADDRESS_1051647] signs and dates the informed consent 
form, in accordance with ISO [ZIP_CODE]. Statistics will be calculated in the intent to treat (ITT) 
population (all subjec ts in whom the Tendyne Mitral Valve System is introduced into the 
body); and Implanted Patient Populations (IPP) (al l subjects in whom the Tendyne Mitral 
Valve implant is completed).    
8.3 Baseline Demographics, Clinical Background, and Protocol 
Administration  
Descriptive statistics will be used to present the data and summarize the results. The study 
population will be summarized  using descriptive stat istics for baseline demographics, 
disease characteristics, echocardiography parameters, procedural characteris tics, and 
follow -up data collected . Continuous variables will be summarized by [CONTACT_766848], Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 43 of 87  of observations (N)  mean, standard deviation, median, minimum and maximum  values .  
Categorical variables will be summarized  using frequency distributions an d cross 
tabulations, incidence and event rate.   Compliance with the protocol will be evaluated by 
[CONTACT_766849], implanted, and completing study required 
follow -ups.  Patients terminating the study early will be listed along w ith the reason for 
termination.   
8.[ADDRESS_1051648] the rate based on the total number of subjects with protocol 
deviations.   
8.5 Evaluation of Primary Endpoints  
8.5.1  Primary Performance  Objec tive  
The primary performance  objective is to estimate the proportion of subjects with MR grade 
≤ [ADDRESS_1051649] -implant .   
Subjects included in the analysis:   All subjects in whom the Tendyne Mitral V alve 
implant is completed.  
Endpoint:   Percentage of subjects with MR grade ≤ [ADDRESS_1051650] -implant .    
Data a nalysis:   The number and percent of subjects associated with each MR grade 
at baseline and [ADDRESS_1051651] implant will be summarized.  The numbe r and 
proportion of subjects with MR grade ≤ 2 at 30 days will be calculated along with the 
95% confidenc e interval for that proportion.  
8.5.2  Primary Safety Objective  
The primary safety objective is to evaluate one -month procedural and device safety of the 
Tend yne Bioprosthetic M itral Valve System .  
Subjects included in the analysis:  All subjects in whom the Tendyne Mitral Valve 
System is introduced into the body.  
Endpoint:  Each of the individual primary safety endpoints will be evaluated (see list 
in 7.3.2  above ).  Additionally, composite endpoints may be estimated and  evaluated 
for comparison to the literature.   
Data a nalysis:  The number of events and the number and percent of patients 
affected by [CONTACT_766850] [ADDRESS_1051652] 95% 
confidence interval.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 44 of 87  8.5.3  Valve System Usability  Objective  
The valve system usability objective is to evaluate information on the usability of the Tendyne 
Bioprosthetic Mitral Valve System . 
Data  included in the analysis:  All usability data gathered from implanters  will be 
analyzed .  Data will be implanters’ assessments of usability, especially as it relates  to 
the ability to successfully deliver, position, and deploy the Tendyne Mitral Valve in 
the desired anatomical location .  Data will also include information on retrievability , 
if available.  
Data Analysis:  Continuous variables will be summarized by [CONTACT_540625], 
standard deviation, median, minimum and maximum.  Categorical vari ables will be 
summarized by [CONTACT_766851].  
8.[ADDRESS_1051653] statistical methods will be 
used to provide estimates along with their 95% confidence intervals.  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 45 of 87  9 Regulations  
This study will be conducted under good clinical practices,  ISO [ZIP_CODE]:2011(E) and ISO 5840 -
3:2013(E) , and when not in contradiction to local standards, laws or requiremen ts, also in 
alignment with the [LOCATION_002] Food and Drug Administration Code of Federal Regulations  
Title [ADDRESS_1051654] agree to comply with this protocol , all ethics committee requirements, and 
all applicable laws and regulations.   
10.2 Initiation Requirements  
Investigative sites may begin enrolling subjects  after all initiation requirements are met and 
the sponsor has given notice of approval to start.  Initiation requirements include : 
institutional review board/ ethics committee approval of this protocol  and the informed 
consen t; training of a ll participating site personnel;  a site initiation visit by [CONTACT_456];  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 46 of 87  training by [CONTACT_247542] ; and submission of all required documents to the sponsor.  
Required documentation includes : institutional review board/ ethics committee approval s; 
curricula  vitae (CVs);  signed investigator agreements with conflict of interest /financial 
disclosure  statements;  documentation of site training ; and any other documents requested 
by [CONTACT_456] . 
10.3 Site  Training  
On-site t raining of investigators and site study personnel will be conducted by  [CONTACT_766852].  Training sessions  may be tailored to fit site personnel’s  role s 
in the study.  The sponsor will ensure adequate training is provided o n the following:  
 Investigational  device , principle of operation and system components  
 Protocol  
 IFU 
 Data collection and eCRFs  
 Investigator responsibilities  
 Device accountability  
 Implantation procedure  
 Imaging and  data acquisition  
 Echo protocol  
 CT protocol  
[ADDRESS_1051655] : explain the  nature, purpose , and consequences of  study  participation to the patient;  
answer any  questions the patient may have;  and provide the patient with the approved 
consent form to read.  The oral informed consent process shall include : an overview of all 
aspects of the written patient information document with specific attention to the volunta ry 
nature of participation ; an overview of study obligations;  risks associated wit h the study 
device implantation;  study procedures ; and alternative treatment modalities.   In addition, the 
possibility to discontinue participation without impact upon on usu al care shall be reviewed 
including requirements for routine clinical follow -up evaluations.  The informed consent 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051656]/ ethics 
committee.  The investigator will inform the patient  with new information , if applicable.  
In the event  a patient has limited or absent legal competence, the process for obtainment of 
informed consent defined by [CONTACT_766853]’s legal 
representative shall be strictly obse rved and undertaken. Insofar  as such a patient, 
independent of legal competence status, is able to understand the nature, purpose and 
consequences of study participation and to make his/her will known, such patient informed 
consent is mandatory, independent of any consent provided by  [CONTACT_5657]/her legal representative.  
Minors, as well as pregnant or nursing women, or women intending to become pregnant in 
the ensuing [ADDRESS_1051657] documents shall be executed in 
conformance with institutional policy : 
• Echocardiography  
• Angiography  
• Computerized Tomographic Angiography (CTA)  
All applicable laws, regulations, and ethics committee requirements must be followed during 
the consent process.   
11.[ADDRESS_1051658] is defined as an individ ual whose willingness to volunteer in a clinical 
investigation could be unduly influenced by [CONTACT_162161], whether justified or not, of 
benefits associated with participation or of retaliatory response from senior members of a 
hierarchy in case of refus al to participate.  
EXAMPLES: Individuals with lack of or loss of autonomy due to immaturity or through mental 
disability, persons in nursing homes, children, impoverished persons, subjects in emergency 
situations, ethnic minority groups, homeless persons,  nomads, refugees, and those incapable 
of giving informed consent. Other vulnerable subjects include, for  example, members of a 
group with a hierarchical structure such as university students, subordinate hospi[INVESTIGATOR_400092], employees of the sponsor, members of the armed forces, and persons 
kept in detention.  
Individuals  who fulfill these criteria shall not be approached for participation in the study.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051659] any part of the Tendyne Mitral Valve System 
introduced into the body will be exited from the study im mediately.  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 49 of 87  12 Methods  
12.1 Overview  
Study methods include testing and collection of data for evaluating the study endpoints, in 
accordance with the clinical data requirements described in ISO 5840.  Table 4, that follows , 
outlines  the study requirements.  
Table 4: Assessments and Data Collection Requirements  
  Exams, Tests and 
Data Collection  Screening
/ Baseline  Procedure  Pre-
discharge  1 
Month
1 3 
Months  6 
Months  1 
year2 2 
years  Annual 
visits  
up to 5 
yrs 
Visit Window   Before and 
After 
Implant  24 hours 
prior to 
discharge
3 -2 days  
+10 days  ±14 
days  ±30 
days  ±45 
days  ±60 
days  ±60 
days  
Informed Consent  X         
Inclusion/Exclusion 
Screening  X         
Medical history 
with Demographics  X         
Physical Exam 
including Vital Signs 
while sitting  X   X X X X X X 
Medications  X X X X X X X X X 
EuroSCORE II  X         
STS Risk Score  X         
CCS Angina class  X         
NYHA class  X   X X X X X X 
Six Minute Hall 
Walk Test  X   X X X X X X 
KCCQ  X   X X X X X X 
CLINICAL LABORATORY TESTS   
Pregnancy Test4 X         
Creatinine  X  X5 X X X X X X 
Plasma –free 
Hemoglobin  X   X X X X X X 
LDH (lactate 
dehydrogenase)  X         
NT pro -BNP  X   X X X X X X 
International 
Normalized Ratio 
(INR)  X  X X X X X X X 
Creatinine Kinase -
MB (CK-MB)  X  X X X X X X X 
Troponin (Type I or 
T) X  X X X X X X X 
INTRAOPERATIVE HEMODYNAMICS (NOT LIMITED TO)9  
CO  X        
PA Pressures   X        
PCWP   X        
LV Pressures   X        
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 50 of 87   
12.2 Echocardiography  
Transesophageal echocardiography (TEE) is required intraoperatively to guide the 
implantation of the Tendyne Mitral Valve  and to assess performance before and after 
placement.  Transthoracic (TTE) echocardiography should be used at all follow -up visits . 
The sponsor will identify an independent echocardiography core laboratory to analyze the 
echo studies.  To  ensure quality imaging and facilitate standardized anal yses, echo protocols 
for both TE E and T TE have been established.  These protocols outline modes of operation and  
imaging views to be obtained.  
This study requires  TEE 3D imaging of the mitral apparatus.  Transthoracic  imaging will be 
2D for assessing mitral, tricuspid, and aortic valves with and without color Doppler and will 
include spectral imaging of these valves as well as the pulmonary veins.  Spectral imaging  of 
the left ventricular outflow track (LVOT) and images needed to assess left ventricular 
volumes and central venous pressures will also be acquired.  
The echo cardiography  core lab will extract indices that include the following:  
• MR grade  
• MR volume and fraction  
• Mitral valve dimensions  EXAMS AND TESTS   
Coronary 
Angiogram  X6         
Cardiac CT  X11   X12      
ECG (12 -Lead)  X7 X8 X       
TEE9 X11 X        
TTE9 X11  X X X X X X X 
Angiography: LV 
Gram   X10        
OTHER   
Device Deficiencies   X        
Adverse Events   X X X X X X X X 
Protocol 
Deviations  X X X X X X X X X 
CCS = Canadian Cardiovascular Society      CTA = Computerized Tomography Angiography     CO = Cardiac Output    ECG = 
Electrocardiogram       eGFR = estimated Glomerular Filtration Rate      NT -proBNP = N -terminal of the prohormone Brain Natriuretic 
Peptide     PA = Pulmonary Arterial     PCWP = Pulmonary Capi[INVESTIGATOR_766810]= Society of Thoracic Surgeons    TEE = 
Transesophageal Echocardiography     TTE = Transthoracic Echocardiography  
 
[ADDRESS_1051660] 6 -months of sc heduled procedure if clinically indicated  
7 Less than or equal to 7 days from Baseline  
8 Before and after implant  
9 LVEF and LVEDD  
10  Optional for subjects with stage 3, 4 or 5 chronic kidney disease (eGFR < 60 mL/min/1.73 m2) 
11 Date of image/testing should be considered clinically relevant per PI  
[ADDRESS_1051661] of care at the hospi[INVESTIGATOR_766811], Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 51 of 87  • LV and LA dimensions  
• Effective regurgitant orifice area (EROA)  
• Mitral valve gradient  
• LVEF  
• Cardiac output  
• LVOT dimensions and gradient  
 
12.[ADDRESS_1051662]’s coronary artery disease status usually will be known in adva nce, via a routine 
diagnostic angiogram done as part of the work -up for cardiac surgery  or transcatheter mitral 
valve repair if clinically indicated .  Any ste nting treatment should be  administered prior to 
the implantation of the Tendyne Mitral Valve  as ou tlined in the patient eligibility criteria  in 
section  6.4 above.  No simultaneous therapeutic procedures should be planned in conjunction 
with the Tendyne Mitral Valve  implantation.  
12.3.1  Preoperative Cardiac Computerized Tomography (CT)  
Cardiac CT is performed as standard of care for transcatheter valve implantation; therefore, 
all subjects will have a Cardiac CT performed at baseline  to evaluate cardiac dimensions 
relevant to valve sizing and aid in procedural planning .  If a cardiac  CT is obtained per non -
research clinical practice  at any follow -up, it should be provided to the study sponsor .   
Additionally, a follow -up cardiac CT should be performed  at the [ADDRESS_1051663] media injected into subjects with compromised renal 
function.  Therefore,  left ventriculogram procedures described in this protocol are optional 
for subjects with stage 3,  4 or 5 chronic kidney disease.  
Tendyne will provide specific instruction on intraoperative imaging requirements as part of 
investigator training.  
12.4 Intraoperative Hemodynamic Measurements  
Subjects will also undergo right -heart catheterization  to measure hem odynamics 
intraoperatively.  Cardiac output (CO) , pulmonary arterial (PA) , aortic and right arterial (RA)  
pressures will be measured before and after the Tendyne Mitral Valve  is placed via the right 
heart  catheter.  LV pressure s should be measured via a pi[INVESTIGATOR_3835].  LV pressures should 
be measured simultaneously and recorded digitally for post -processing analysis if possible.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051664] be taken 
includ ing co -morbidities and co -existing medical conditions; previous cardiovascular and 
peripheral vascular interventions; symptoms and diagnosis of mitral insufficiency.  
12.[ADDRESS_1051665] be evaluated at 
baseline and each scheduled follow -up visit.  Vital signs include sitting pulse, sitting blood 
pressure and body temperature.   
12.7 Kansas City Cardiomyopathy Questionnaire (KCCQ)  
The KCCQ is a heart failure specific measure of health status and quality of life.  It is a [ADDRESS_1051666] be done at baseline  and each scheduled follow -up visit.  
Assessments include : NT-proBNP , plasma free hemoglobin , serum creatinine, and 
International Normalized Ratio (INR) . Creatinine k inase -MB (CK -MB)  and/or  Troponin (Type 
I or T)  should also be collected according to standard of care at the clinical site.  Additionally, 
serum creatinine , INR, CK -MB/Troponin  must be assessed at pre-discharge . 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051667] be recorded at baseline,  intraoperatively  both before and after implant  
and at pre -discharge.  
12.12  Adverse Events  
All adverse events (AEs) that occur to any subject during study participation must be 
documented on an AE case report form (CRF).  Refer to Section [ADDRESS_1051668]. Paul , Minnesota,  5511 7 
[LOCATION_003]  
 
Vigilance Officer:  
Allison Genereau  
Sr. Safety Specialist  
[ADDRESS_1051669]  
Maple Grove, MN [ZIP_CODE]  
Tel: [PHONE_15995] -756 -5436  
E-mail: [EMAIL_14644]  
 
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 54 of 87  13 Implant Procedure  
13.1 Requirements  
The implant should be performed by [CONTACT_766854] (See Section 10.1 ).  The 
cardiac surgeon should be the primary operator.   
The following equipment is requir ed for implantation:  
• Standard cardiac catheterization lab equipment  
• Fluoroscopy equipment appropriate for use in cardiac interventions  
• Transesophageal echocardiographic equipment  
• Angiographic equipment  
For backup purposes, the following are needed:  
• Circula tory support  
• Temporary pacing equipment  
• Defibrillator  
 
13.[ADDRESS_1051670] for the implant procedure as follows:  
• Administer general anesthesia.  
• Attach a 12 -lead ECG  (if not obtained immediately prior) . 
• Prepare the subject for a left mini -thoracotomy.  
• Prepare the subject for TEE.  
• Prepare the subject for right - and left -heart catheterizati on. 
The subject must be on anticoagulant typi[INVESTIGATOR_766812].  
Activated clotting time (ACT) is to be maintained at >250 seconds for the duration of the 
procedure.  
 
13.3 Initial Data Acquisition  
Tendyne will provide specific instruction on intraoperative imaging and data acquisition 
requirements as part of investigator training.  A brief overview is provided here.  
Using cardiac catheters, obtain the required measurements, including the following:  
• Cardiac output using thermodilution method  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 55 of 87  • Intracardiac and vascular pressures  
Perform the intraoperative TEE protocol  to obtain views and measurements pertaining to the 
mitral valve and left ventricular function.  
13.4 Implant Procedure  
An overview of the recommended Tendyne Mitra l Valve  implant procedure is provided here.  
Refer to the Instructions for Use for additional detail.   
13.4.1  Valve Placement  
1. Ensure that all components are fully de -aired to avoid introducing air emboli into 
the heart, and continue to flush them with isotonic saline throughout the procedure.  
2. Thoroughly rinse the valve with heparinized isotonic saline.  
3. Compress and load the valve into the instrument, ensuring that the proud anterior 
segment is properly aligned with the corresponding marker on the instru ment.  
4. Determine the proper trajectory from the patient’s left ventricular apex to the mitral 
valve.  Puncture the apex and insert a standard .035” guidewire.  
5. Ensure a path clear of entanglement in the chordae.  
6. Advance the instrument over the guidewire to achieve access to the left ventricle.  
Further advance it across the mitral valve and into the left atrium.   
7. Deploy the valve, while observing the deployment using echo and/or fluoroscopic 
imaging.   
8. Pull the v alve proximally into the mitral annulus ensuring that the proud anterior 
cuff is oriented toward the aortic -mitral continuity.  
9. Using echo and/or fluoroscopic imaging, confirm that the valve is oriented correctly.  
a) If the valve needs to be repositioned, use the instrument to partially recapture the 
valve, push it up into the left atrium, reorient, and pull it back into position.  
b) If the valve is the wrong size or otherwise needs to be withdrawn, use the 
instrument to fully recapture the valve and pull it out t hrough the api[INVESTIGATOR_766788].  If 
desired, an alternative valve can be deployed.  
10. Once proper orientation has been confirmed, adjust tension using the api[INVESTIGATOR_766813] g. 
11. Once stability is achieved and valve function is determined to be acceptable, remove 
the instrument and fasten the api[INVESTIGATOR_766814].   
13.4.2  Valve Verification  
1. Monitor the function of the implanted valve with periodic TEE.  
2. Measure the cardiac output a nd cardiac index.  
3. Measure transmitral pressure gradient (mean and peak).  
4. Measure aortic and right arterial (RA) pressures . 
5. Optionally p erform a left ventriculogram.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051671] -operative period, the subjec t’s blood pressure is to be closely 
monitored and maintained below 135 mmHg systolic if possible.    
Subjects are required to  be on anticoagulation  therapy , warfarin  with a target INR  range of 
2.5 to 3 .5, for a minimum of  three months .  Antiplatelet therapy may also be administered 
during this timeframe.  Thereafter , subjects  should be on aspi[INVESTIGATOR_766815].   
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 57 of 87  14 Follow -up Visits  
14.1  Pre-Discharge  
Pre-discharge data collection is to be done within 24 hours prior to  discharge (or, in the event  
of prolonged hospi[INVESTIGATOR_059], within 10 days after the implant procedure).  Pre -discharge 
requirements include clinical status, medications, an ECG , and documentation of any peri -
operative AEs.  It is recommended that serum creatinine be assessed at  appr oximately [ADDRESS_1051672] occur at the following time points following implantation:  
 Pre-discharge  Within [ADDRESS_1051673]  
 One month  28 - 40 days  
 Three months  90 ± 14 days  
 Six months  180 ± 30 days  
 One year  365 ± 45 days  
 Two years  730 ± 60 days  
 Annually thereafter until [ADDRESS_1051674] be completed using the appropriate CRF.  
14.3 Study Exit  
After the 2-year  study visit, subjects should be followed annually until study completion and 
closure.  Consistent with ongoing, interim communication with each patient’s community 
care physician/cardiologist, upon study completion, each patient will be re turned to the full 
care of such patient -identified physicians. The clinical study team shall remain available to 
each patient’s community care physician in the event of any specific follow -up evaluations 
and consultations.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051675] present s for an unscheduled visit due to an AE that is  serious (SAE) and/ or device - 
or procedure -related , the following are required: cli nical status ; medication changes ; and 
documentation of the  AE using the appropriate eCRFs .   
14.[ADDRESS_1051676] make repeated attempts (at 
least three) to contact [CONTACT_102].  If a patient cannot be contact[CONTACT_766855], the investigator 
should contact a third person (normally the patient's general practitioner) to get information 
about the patients' health. The permission and the contact [CONTACT_766856]. Each attempt and the method used (e.g., telephone) must be 
documented in the patient’s recor ds.  A subject who is lost to further follow -up must be 
reported to the sponsor using the appropriate eCRF.  
14.[ADDRESS_1051677]’s study participation, the physician should obtain image data and 
otherwise attempt to characterize the valve  in situ , to the extent feasible . 
If an open -chest procedure is performed, then photographs should be tak en.  Photographs 
should be taken of the v alve and/or native tissues before and after any modification or 
explant is done.  The sponsor is particularly interested in understanding host response to the 
implanted v alve (tissue ingrowth) and other device -host interfaces such as potential damage 
to native tissues including native leaflets, subvalvular structures and myocardium.   
If a v alve is explanted, the valve  should immediately be placed in 10% neutral buffered 
formalin and return ed to the sponsor for analy sis.  The valve  must be handled carefully and 
as little as possible to prevent dam age and preserve its integrity.  The sponsor must be 
contact[CONTACT_766857][INVESTIGATOR_766816].  
All rel evant data pertaining to the re interv ention or explant must be documented on the 
appropriate eCRF.  The physician should dictate an operative report and submit it to the 
sponsor along with any image data and photographs.  
[ADDRESS_1051678] will be assigned a unique identification code (ID) for the purpose of identity 
protection.  Any subject names that may inadvertently appear on study documents  submitted 
to the sponsor will be redacted upon receipt . 
17.2 Central Database  
All study d ocumentation will be collected and compi[INVESTIGATOR_40177] a central database.  Appropriate 
quality control measures will be established to ensure accurate and complete transfer of 
information from the study documentation to the central database.  
17.3 Electronic Case Repor t Forms  (eCRF)  
Electronic c ase report forms are designed to capture study data.  The investigator is 
responsible for completing a ll appropriate sections of the eCRFs and submitting them  to the 
sponsor in a timely manner.  The investigator is also responsib le for responding to queries 
(e.g., data clarification forms) from the sponsor to clarify any pending questions  about the 
data.  
17.[ADDRESS_1051679]/ ethics 
committee as soon as possible of any deviation from this protocol  that was done to protect 
the life or physical well -being of a subject.  
17.[ADDRESS_1051680] 
checks such as range checks will be incorporated into the central database.  Data clarification 
Forms (DCFs) will be issued to resolve data discrepancies.  Study monitoring will be 
conducted to ensure that the site is submitting complete and accurate data, and to verify 
source data.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051681] 
names.  
When required by [CONTACT_2371], consistent with the specifications of Annex VII of Council Directive 
93/42/EEC, patient identification information,  patient consent, individual patient clinical 
course documentation, as well as documentation of regulatory compliance with clinical study 
legal requirements shall be retained by [CONTACT_110602] a minimum period of 15 
years (implantable medical  devices).  Original clinical data documentation provided for study 
analysis, as well as such documentation of regulatory conformance with legal requirements 
shall be retained by [CONTACT_766858] a period of [ADDRESS_1051682]/ ethics committee 
approvals and correspondence.   
Monitors will conduct site visits to ensure accuracy of data, timeliness of data submission, 
adequate patient enrollment, compliance with applicable laws and regulations, compliance 
with this protocol , compliance with the signed investigator agreement, and  compliance with 
institutional review board/ ethics committee conditions and guidelines.  Any noncompliance 
with these items that is not adequately addressed by [CONTACT_766859].   
The site staff must be available to meet with the monitor or other sponsor representative 
during monitoring visits.  The investigator must allow monitoring by [CONTACT_766860] r local governmental body to review the study 
subjects’ medical records, including any test or laboratory data.  
Frequency of monitoring will be based on enrollment, study duration, site compliance, and 
any suspected inconsistency in data that requires inve stigation.  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 62 of 87  18 Adverse Event Reporting  
An adverse event ( AE) is defined as any untoward medical occurrence in a study subject, 
which does not necessarily have to have a causal relationship with study treatment.  An AE 
can be an unfavorable and unintended sig n (including an abnormal laboratory finding), 
symptom or disease, temporary or permanent, whether or not related to the prosthetic valve 
implantation or procedure.  Refer to [ADDRESS_1051683]’s exit from the study.  Any AE that occurs to any subject during the study must be 
documented on an AE electronic case report form.   Information collected includ es: date of 
onset of first observation;  description of the event ; seriousness;  causal relationship to the 
device ; causal relationship to the procedure ; treatment required;  and o utcome or status of 
the event.  
Serious Adverse Events (SAE) require reporting w ithout delay to the Competent Authorities. 
In such cases, the investigator will inform the Sponsor immediately , but not later than [ADDRESS_1051684] comply with all reporting requirements of the 
ethics committees and applicable laws and regulations.  
18.1 Adverse Event (AE)  Review and Classification  
All AEs will be reviewed and classified by a Clinical Events Committee (CEC).  In addition, a 
Data and Safety Monitoring Board (DSMB) may review AE data as it relates to their role.  Refer 
to Sections 19.5  and 19.6  for more information.  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 63 of 87  18.2 Anticipated AEs  
Anticipated AEs are those that may be reasonably expected to occur in association with a 
surgical or transcatheter valve procedure.  Anticipated AEs include , but are not limited to,  
those listed here ; those repor ted in the risk analysis rep ort; those reported in the IFU;  and 
those reported in the literature associated with valve procedures:  
 Adverse foreign body response  
 Adverse reaction to anesthesia  
 Allergic reaction  
 Anemia  
 Annular dissection  
 Aortic insufficiency  
 Atrial or ventricular injury  
 Bioprosthetic valve dysfunction  
 Bleeding complications  
 Blood loss which may require transfusion  
 Cardiac arrest  
 Cardiac perforation  
 Conduction defect with or without need for 
pacemaker  
 Cardiac arrhythmia, Atrial or Ventricular  
 Damage to cardiac tissue and/or structures  
 Death  
 Decreased LV function and/or cardiac output  
 Device embolism  
 Device erosion, migration or malposition  
 Device thrombosis  
 Embolism (device, air, blood clot, tissue, etc.)  
 Endocarditis  
 Esophageal irrit ation, st ricture or perforation  
 Foreign Body Response   Fever  
 Heart Failure, new or worsening  
 Hematoma  
 Hemolysis  
 Hypotension  
 Infection / Sepsis  
 Liver failure  
 Mitral valve injury  
 Mitral valve prolapse / stenosis  
 Myocardial infarction  
 Obstruction  
 Pain  
 Pleural effusion  
 Pulmonary embolism  
 Pulmonary hypertension  
 Paravalvular leak  
 Pericardial effusion / tamponade  
 Renal insufficiency or failure  
 Respi[INVESTIGATOR_60319], insufficiency or 
failure  
 Stroke or transient ischemic attack  
 Tear or damage to device  
 Vascular and  access -related 
complications  
 Worsening of mitral regurgitation  
 
18.[ADDRESS_1051685] categorize each AE as either serious (SAE) or non -serious, according 
to the definition in  22.  Final classifications will be made by [CONTACT_15741].   
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051686] be documented and 
communicated to the sponsor as soon as possible, preferably within 24 hours of knowledge 
of the event.  If a failed or malfunctioning Tendyne Mitral Valve  is explanted, it should be 
returned to the sponsor  as biohazardous material without re -sterilization and reuse .  
Procedures for returning exp lanted devices are detailed in S ection 15.  All other device 
deficiencies should be reported to the sponsor on the appropriate eCRF as technical 
observations.   
19 Responsibilities  
This study will be performed in conformance with t his protocol  and all applicable laws and 
regulations.  
19.1 Investigator  Responsibilities  
The investigator is responsible for ensuring the study is conducted according to all signed 
agreements, this protocol , the reviewing ethics committee, and all applicable la ws and 
regulations.  Investigator responsibilities include, but are not limited to, the following:  
 Assume responsibility for proper conduct of the clinical study.  
 Disclose potential conflicts of interest, including financial, that may interfere with the 
conduct of the study or interpretation of results, and promptly update this 
information if any relevant changes occur during the course of the study.  
 Submit this protocol  and the sponsor -approved informed consent form (ICF) to the 
reviewing ethics committe e, and obtain written approval before beginning study 
participation.  
 Fulfill any conditions of approval imposed by [CONTACT_21980]/ ethics 
committee, such as regular reporting.  
 Provide the sponsor with copi[INVESTIGATOR_766817].  
 Comply with the informed consent procedures, using the approved ICF.  
 Ensure that the investigational device is used solely by [CONTACT_766861].  
 Maintain accurate, complete, and curr ent records relating to the conduct of the study.  
 Report study data and any protocol deviations to the sponsor promptly.  
 Report adverse events, device deficiencies and device malfunctions to the sponsor 
(and to the institutional review board/ ethics committ ee as required) promptly.  
 Make available, at the sponsor’s request, all study -related data (including source 
documentation) and study -related documentation (including institutional review 
board/ ethics committee approvals and correspondence) for monitoring or auditing 
purposes.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 65 of 87  19.2 Sponsor  Responsibilities  
Tendyne is the sponsor of this study.  Sponsor responsibilities include, but are not limited to, 
the following:  
 Select and qualify investigative sites and principal investigators.  
 Provide training to investigators and investigative site staff.  
 Ensure approval/permission from regulatory body as required by [CONTACT_13736].  
 Select qualified monitors and ensure that adequate monitoring of clinical data occurs 
at the investigative sites.  
 Retain ownership of all  data generated in this study, and control the use of the data 
for appropriate purposes only.   
 Collaborate with investigators on publishing study results.  
19.[ADDRESS_1051687] operating procedures.  The  data will then be transferred to 
and reported by [CONTACT_456].  
 [LOCATION_011]/[LOCATION_003] Echocardiography Core Lab  
Beth Israel Deaconess Medical Center,  
[ADDRESS_1051688] Floor, [LOCATION_011], MA [ZIP_CODE], [LOCATION_003]  
Michael Chaung  
[EMAIL_14643]  
 
19.[ADDRESS_1051689] operating procedures.  The data will then be 
transferred to and reported by [CONTACT_456].  
 SPH/UBC Cardiac CT Core Lab  
University of British Columbia, [ADDRESS_1051690],  
Vancouver, British Columbia, V6T 1Z3, Canada  
Department of Radio logy ‐ St. Paul’s Hospi[INVESTIGATOR_766790]. Jonathon Leipsic : [EMAIL_14641]  
[CONTACT_766882] : [EMAIL_14642]  
 
It is a responsibility of the Core Laboratories to evaluate whether a subject is suitable for 
treatment with the Tendyne Mitral Valve  and select the most suitable valve model and size 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 66 of 87  based on the imaging evaluation of the individual’s mitral valve by [CONTACT_766862] .  The anatomy of the mitral valve is 
complex and highly variable between subjects. For this reason, it is not possible to determine 
generic criteria applicable to all subjects, and an i n-depth evaluation must be performed in 
every single candidate by [CONTACT_766863]. 
Mitral valve modeling is performed with the aid of special software :  Circle cardiovascular 
imaging software, www.circlecvi.com a s recently published by [CONTACT_50338] ;98 and Mimics 
(biomedical.materialise.com/mimics) for medical image segmentation and engineering on 
anatomy . The anatomical suitability is documented in each subject, see example in the IB 
(Appendix 2, Pre -procedural pl an example).  
19.5 Clinical Events Committee (CEC)  
An independent Clinical Events Committee (CEC) will be established.  The CEC will consist of 
clinicians who are not investigators in the study and who do not have any significant 
investment in the sponsor or its  competition.  At least three cl inicians will serve on the CEC.  
The CEC will be responsible for reviewing and classifying all serious adverse events, device -
related adverse events, and  deaths.  Refer to  [ADDRESS_1051691] (DSMB)  
An independent Data and Safety Monitoring Board (DSMB) will be established.  Members will 
not have any significant investment in the sponsor or its competition.  The DSMB will consist 
of one statistician and at least two physicians .   
The role of the DSMB will be to monitor the overall conduct of the study, the rights, safety, 
and welfare of the study participants, and to evaluate interim data to determine if there are 
any specific safety concerns.  The DSMB will be responsible for communicating  any safety or 
scientific concerns or perceived problems with the study to the sponsor as soon as possible.  
At the conclusion of each DSMB meeting, a recommendation will be made to the sponsor on 
whether to continue, suspend, modify, or stop the study.  
The DSMB will meet periodically throughout the study.  DSMB operations will be determined 
early in the study and formalized in a DSMB charter.  DSMB activities and members may 
overlap with the CEC as appropriate.  
19.7 Publications Committee  
The sponsor may form  a publications committee to make decisions regarding authorship and 
content of publications.  The publications committee’s mission would be to construct a plan 
for topi[INVESTIGATOR_766818].  Any investigator intending to publish should inform the 
sponsor and attempt to collaborate.   
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051692] maintain a log to document the status/location of each 
investigational device provided by [CONTACT_758123].  The log will include the 
following as applicable:  date of receipt, lot number , subject ID, disposition, reason , quantity  
and date of return to sponsor.  Devices allocated to a site  must be stored in a secured area 
until used.  All explanted devices  must be returned to the sponsor.   
Procedures for returning explanted devices are provid ed in Section 15.  At study closeout, the 
sponsor will collect all unused devices.  
21 Study Closure  
21.1 Suspension or Early Termination  
The entire study or any individual site may be suspended or terminated prematurely by [CONTACT_766864].  In the 
event of suspension or early termination, the sponsor will promptly inform pri ncipal 
investigators and ensure that institutional review boards/ ethics committees are notified of 
the stoppage and the reason for it  in line with Medical Device Directive 93/42/EEC Article 
15.[ADDRESS_1051693] 
retention, and institutional review boards/ ethics committees are notified.  
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 68 of 87  22 Appendix A  
 
Normative References  
 
ISO [ZIP_CODE]   ISO [ZIP_CODE]:2011(E). Clinical investigation of medical devices for human 
subjects — Good clinical practice.  
 
ISO 5840 -3  ISO 5840 -3:2013(E). Cardiovascular implants — Cardiac valve prostheses — 
Part 3: Heart valve substitutes implanted by [CONTACT_766865] s. 
 
 
Adverse Device Effect (from ISO [ZIP_CODE] ) 
Adverse event related to the use of an investigational medical device.  
 
Adverse Event   
Events that fall under the definition of Adverse Event from either ISO [ZIP_CODE] or ISO 58 40-3: 
(from ISO [ZIP_CODE])  Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, users or other 
persons, whether or not related to the investigational medical device.  
Note 1  This definition includes events related to the investigational medical device 
or the comparator.  
Note 2  This definition includes events related to the procedures involved.  
Note 3  For users or other persons, this definition is restricted to events related to  
investigational medical devices.  
 
(from ISO 5840 -3)  Untoward medical occurrence in a study subject, which  does not 
necessarily have to have a causal relationship with study treatment.  
 
Bleeding (from BARC)  
Six types are hierarchically defined from type 0 in which there is no bleeding to type 5 with 
fatal bleeding. Type 1 is in which the patient does not seek treatment. Type 2 is in which 
intervention or admission to hospi[INVESTIGATOR_766819]. Type 3a is overt bleeding plus hemoglobin drop 
of 3 to less than 5 g/dl or transfusion. Type 3b is overt bleeding plus hemoglobin drop of at 
least 5 g/dl, cardiac tamponade, bleedi ng requiring surgical intervention or intravenous 
vasoactive agents. Type 3c is intracranial hemorrhage or intraocular bleeding compromising 
vision. Type 4 is coronary artery by[CONTACT_15806] -related bleeding and type 5 is fatal bleeding.  
 
Body Surface Area  (from ISO 5840 -3) 
Total surface area (m2) of the human body.  NOTE :  This can be calculated (Mosteller’s 
formula) as the square root of product of the weight in kg times the height in cm divided by 
3600.  
 
Cardiac Index  (from ISO 5840 -3) 
Cardiac output divided by [CONTACT_766866] L /min/m2. 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 69 of 87   
Cardiovascular Death (from VARC II)  
Any of the following criteria:  
• Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, 
worsening heart failure)  
• Death caus ed by [CONTACT_105] -coronary vascular conditions such as neurological events, 
pulmonary embolism , ruptured aortic aneurysm, dissecting aneurysm, or other 
vascular disease  
• All procedure -related deaths, including those related to a complication of the 
procedure or tre atment for a complication of the procedure  
• All valve -related deaths including structural or non -structural valve dysfunction or 
other valve -related adverse events  
• Sudden or unwitnessed death  
• Death of unknown cause  
Non -cardiovascular death is any death in w hich the primary cause of death is clearly related 
to another condition (e.g., tra uma, cancer, suicide).  
 
Causal Relationship (from ISO 5840 -3) 
Causal relationship is the relationship of the AE to the study device, the implant procedure or 
the patient’s co ndition.  It should be established in line with the following categories:  
• Device -related:   Any AE involving the function of the device, or the presence of the 
device in the body.  Included in this category are events that are directly attributed to 
the device.  
• Procedure -related:   Any AE that results from the implant procedure.  Events in this 
category are directly related to the general procedural sequelae.  
• Patient condition -related:   Any AE that results from the worsening of a pre -existing 
condition or cannot be attributed to the device procedure.  
• Unknown:   Any AE that cannot be assigned to an y of the above three conditions.  
 
Chronic Kidney Disease, Stages  (from National Institute  for Health & Clinical Excellence.  
Clinical Guideline 73: Chronic Kidney Disease, London 2008)  
• Stage 1:  Slightly diminished function; kidney damage with normal or relatively high 
GFR (≥90 mL/min/1.73 m2). Kidney damage is defined as pathological abnormalities 
or markers of damage, including abnormalities in blood or urine test or imaging 
studies.  
• Stage 2 :  Mild reduction in GFR (60 –89 mL/min/1.73 m2) with kidney dam age. 
Kidney damage is defined as pathological abnormalities or markers of damage, 
including abnormalities in blood or urine test or imaging studies.  
• Stage 3 :  Moderate reduction in GFR (30 –59 mL/min/1.73 m2). British guidelines 
distinguish between stage 3A  (GFR 45 –59) and stage 3B (GFR 30 –44) for purposes of 
screening and referral.  
• Stage 4 :  Severe reduction in GFR (15 –29 mL/min/1.73 m2) Preparation for renal 
replacement therapy.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 70 of 87  • Stage 5 :  Established kidne y failure (GFR <15 mL/min/1.73 m2) , permanent renal  
replacement therapy , or end stage renal disease . 
 
Cycle  (from ISO 5840 -3) 
One complete sequence in the action of a heart valve substitute under pulsatile flow 
conditions.  
 
Cont ract Research Organization  (from ISO [ZIP_CODE])  
Person or organization contracted b y the sponsor to perform one or more of the sponsor’s 
clinical investigation -related duties and functions.  
 
Data Monitoring Committee /Data and Safety Monitoring Board  (from ISO [ZIP_CODE])  
Independent committee that may be established by [CONTACT_766867], at intervals, the 
progress of the clinical investigation, the safety data or the critical performance endpoints 
and to recommend the sponsor whether to continue, suspend, modify, or stop the clinical 
investigation.  
 
Device Deficiency  (from ISO [ZIP_CODE])  
Inade quacy of a medical device with respect to its identity, quality, durability, reliability, 
safety or performance.  NOTE :  Device deficiencies include malfunctions, use errors, and 
inadequate labeling.  
 
Device Embolization  (from ISO 5840 -3) 
Dislodg ment from the intended and documented original position to an unintended and non -
therapeutic location.  
 
Device Failure  (from ISO [ZIP_CODE] and  ISO 5840 -3) 
Inability of a device to perform its intended function sufficient to cause a hazard.  
 
Device Migration  (from ISO 5840 -3) 
Detectable movement or displacement of the device from its original position within the 
implant site, without embolization.  
 
Ethics Committee  (from ISO [ZIP_CODE])  
Independent body whose responsibility it is to review clinical investigations in order to 
protect the rights, safety, and well -being of human subjects participating in a clinical 
investigation.  NOTE :  “Ethics Committee” is synonymous with “research ethics committee”, 
“independent ethics committee” or “institutional review board”.  The regulatory 
requirements pertaining to ethics committees or similar institutions vary by [CONTACT_766868].  
 
Follow -up (from ISO 5840 -3) 
Continued assessment of patients who have received the heart valve substitute.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 71 of 87   
Heart Valve Substitute  (from ISO 584 0-3) 
Device used to replace the function of a natural valve of the heart.  
 
Implant Site  (from ISO 5840 -3) 
Intended site of transcatheter heart valve substitute deployment.  
 
Informed Consent Process  (from ISO [ZIP_CODE])  
Process by [CONTACT_766869] d information and is asked to voluntarily participate 
in a clinical investigation.  NOTE :  Informed consent is documented by [CONTACT_3553] a written, 
signed and dated informed consent form.  
 
Intended Use  (from ISO 5840 -3) 
Use of a product, process or service in  accordance with the specifications, instructions and 
information provided by [CONTACT_3455].  
 
Investigation Site /Investigational Site  (from ISO [ZIP_CODE])  
Institution or site where the clinical investigation is carried out.  NOTE :  “Investigation site” 
is synon ymous with “investigation centre ”. 
 
Investigational Device/Investigational Medical Device (from ISO [ZIP_CODE])  
Medical device being assessed for safety or performance in a clinical investigation.  
 
Investigator (from ISO [ZIP_CODE])  
Individual member of the investigation site team designated and supervised the principal 
investigator [INVESTIGATOR_766820] -investigation -related 
procedures or to make important clinical -investigation -related decisions.  NOT E:  An 
individual member of the investigation site team can also be called “sub -investigator” or “co -
investigator”.  
 
Legally Authorized Representative  (from ISO [ZIP_CODE])  
Individual or judicial or other body authorized under applicable law to consent, on beha lf of 
a prospective subject, to the subject’s participation in the clinical investigation.  
 
Malfunction  (from ISO [ZIP_CODE])  
Failure of an investigational medical device to perform in accordance with its intended 
purpose when used in accordance with the instru ctions for use or clinical study protocol.  
 
Myocardial Infarction, Peri -procedural  (from VARC II)  
Peri -procedural is ≤72 hours after the index procedure.  
• New ischemic  symptoms (e.g., chest pain or shortness of breath), or new ischemic  
signs (e.g., ventric ular arrhythmias, new or worsening heart failure, new ST -segment 
changes, hemodynamic  instability, new pathological Q -waves in at least two 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 72 of 87  contiguous  leads, imaging evidence of new loss of viable myocardium or new wall 
motion abnormality) AND  
• Elevated car diac biomarkers (preferable CK -MB) within [ADDRESS_1051694] -procedure with a peak value 
exceeding 15 x as the upper reference limit for troponin or 5 x for CK -MB.  If cardiac 
biomarkers are increased at baseline (> 99th percentile), a further increa se in at least 
50% post -procedure is required AND the peak value must exceed the previously 
stated limit.  
 
Myocardial Infarction , Spontaneous  (from VARC II)  
Spontaneous is prior to or >72 hours after the index procedure.  
Any one of the following criteria:  
• Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least 
one value above the 99th percentile URL, together with the evidence  of myocardial  
ischemia  with at least one of the following:  
o Symptoms of ischemia  
o ECG changes indicative of new ischemia  (new ST -T changes or new left bundle 
branch block (LBBB))  
o New pathological Q -waves in at least two contiguous leads  
o Imaging evidence of a new loss of viable myocardium or new wall motion 
abnormality  
o Sudden, unexpected  cardiac death , involving cardiac arrest , often with 
symptoms suggestive of myocardial ischemia , and accompanied by 
[CONTACT_766870], or new LBBB, and/or evidence of fresh 
thrombus by [CONTACT_766871]/or at autopsy, but death occurring 
before blood samples could be obtained, or at a time before the appearance of 
cardiac biomarkers in the blood.  
o Pathological findings of an acute myocardial infarction.  
 
Non -Structural Valve Dysfunction (from ISO 5840 -3) 
Abnormality extrinsic to the transcat heter heart valve substitute that results in valve 
dysfunction (stenosis, regurgitation, or both).  
 
Principal Investigator (from ISO [ZIP_CODE])  
Qualified person responsible for conducting the clinical investigation at an investigation site.  
NOTE :  If a clinic al investigation is conducted by a team of individuals at an investigation site, 
the principal investigator [INVESTIGATOR_292155].  
 
Protocol Deviation  
Instance of failure to follow, intentionally or unintentionally, the requirements of the cl inical 
study protocol.  
 
Regurgitant Fraction  (from ISO 5840 -3) 
Regurgitant volume expressed as a percentage of the forward flow volume.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 73 of 87   
Repositioning  (from ISO 5840 -3) 
Change in implant position of a partially or fully deployed transcatheter heart valve  
substitute via a transcatheter technique, possibly requiring full or partial recapturing of the 
device.  
 
Retrieval  (from ISO 5840 -3) 
Removal of a partially or fully deplo yed transcatheter heart valve substitute via a 
transcatheter technique.  
 
Serious Adverse Device Effect (SADE)  (from ISO [ZIP_CODE])  
Adverse device effect that has resulted in any of the consequences characteristic of a serious 
adverse event.  
 
Serious Adverse Event (from ISO [ZIP_CODE])  
Adverse event that  
a) Led to death,  
b) Led to serious deterioration in the health of the subject, that either resulted in  
1) A life-threatening illness or injury, or  
2) A permanent impairment  of a body structure or a body functio n, or  
3) In-patient or prolonged hospi[INVESTIGATOR_059], or  
4) Medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function,  
c) Led to fetal  distress, fetal  death or a congenital abnormali ty or birth defect.  
NOTE :  Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_60658], without serious deterioration in health, is not considered a serious adverse 
event.  
 
Severity  (from ISO 5840 -3) 
Measure of the p ossible consequences of a hazard.  
 
Source Data  (from ISO [ZIP_CODE])  
All information in original records, certified copi[INVESTIGATOR_34504], 
observations, or other activities in a clinical investigation, necessary for the reconstruction 
and evaluation of the clinical investigation.  
 
Source Document  (from ISO [ZIP_CODE])  
Printed, optical, or electronic document containing source data.  
 
Stroke and TIA (from VARC II)  
Diagnostic c riteria:  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 74 of 87  • Acute epi[INVESTIGATOR_44715] a focal or global neurological deficit with at least one of the following:  
change in the level of consciousness, hemiplegia, hemiparesis, numbness, or sensory 
loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis 
fugax, or other neurological signs or symptoms  consistent with stroke.  
• Stroke:  Duration of a focal or global neurological deficit ≥24 hours; OR <[ADDRESS_1051695]; OR the neurological 
deficit results in death.  
• TIA:  Duration of a focal or global neurological deficit <[ADDRESS_1051696].  
• No other readily identifiable non -stroke cause for th e clinical presentation (e.g., brain 
tumor , trauma, infection, hypoglycemia , peripheral lesion, pharmacological 
influences), to be determined by [CONTACT_766872].  
• Confirmation of the diagnosis by [CONTACT_080]:  
o Neuro logist or neurosurgical specialist  
o Neuroimaging procedure (CT scan or brain MRI), but stroke may be 
diagnosed on clinical grounds alone.  
• Disabling Stroke :  A modified Rankin Scale (mRS) score of [ADDRESS_1051697] one mRS cate gory from an individual’s pre -stroke baseline.  
• Non -disabling Stroke :  An mRS score of <[ADDRESS_1051698] one mRS category from an individual’s pre -stroke baseline.  
 
Stroke Classification  
A stroke may be cla ssified as undetermined if there is insufficient information to allow 
categorization as ischemic  or hemorrhagic . 
• Ischemic :  An acute epi[INVESTIGATOR_196545], spi[INVESTIGATOR_1304], or retinal dysfunction caused by 
[CONTACT_766873].  
• Hemorr hagic :  An acute epi[INVESTIGATOR_766821], intraventricular, or su barachnoid hemorrhage . 
 
Structural Valve Dysfunction  (from ISO 5840 -3) 
Structural abnormality intrinsic to the transcatheter heart valve substitute that results in 
valve dysfunction (stenosis and/or transvalvular and/or paravalvular  regurgitation)  
 
Subject  (from ISO [ZIP_CODE])  
Individual who participates in a clinical investigation.  
 
Usability  (from ISO 5840 -3) 
Characteristic of the user interface that established effectiveness, efficiency, ease of user 
learning and user satisfaction.  
 
Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE) (from ISO [ZIP_CODE])  
Serious adverse device effect which by [CONTACT_5942], incidence, severity or outcome has not been 
identified in the current version of the risk analysis report.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 75 of 87   
Use Error  (ISO [ZIP_CODE])  
Act or omission of an act that results in a different medical device response than intended  by 
[CONTACT_3460].  
 
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051699] -market setting, to capture long -term d ata 
on less common or unanticipated adverse events, on adverse events which are time -related 
(e.g. , structural deterioration, adverse effects on native valve anatomy) and on long -term 
performance.  
As e nrollment will continue in the post-market phase, subgr oup analyses are planned in a 
broader patient group , up to  350 patients , to evaluate the  safety  and performance profile  of 
the Tendyne Mitral Valve  in primary and secondary MR, and to analy ze and compare data for 
different valve sizes . 
All statistical analyses will be performed using Statistical Analysis System (SAS) for Windows 
(version 9.4, SAS Institute Inc. Cary, NC) or other widely accepted statistical or graphical 
software.   
23.3  Hypotheses (HO, HA) for 30-day mortality  
Safety will be  evaluated by [CONTACT_29847] 30 -day mortality in comparison to other MV 
replacement devices using the following hypothesis:  
Ho: P ≥ 20%  
Ha: P < 20%,  
Where P is the proportion of subjects that died within the first 30 days, and the performance 
goal of 20% is based upon an assumption of true mortality of 8% with a non -inferiority 
margin of 12%.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 77 of 87  23.4 Calculation of Sample S ize for Mortality   
The estimated mortality of mitral valve replacement at 30 days is expected to be around 7 -
9% based upon in -hospi[INVESTIGATOR_766822]. We will assume the true mortality at 30 days is in the middle at 
approximately 8%.   
 
Table 5 Estimated Mortality  
 In-hospi[INVESTIGATOR_766823].,  
Circulation. 2003;  
108:298 -304  6.90%  4.30%  
Vassileva et al.,  
Circulation. 2013;  
127: 1870 -1876.  8.90%  3.90%  
 
Allowing a 12% Non -Inferiority  margin and a one -sided alpha of 0.05, a sample size of [ADDRESS_1051700] 80% power to test against the  mortality  performance goal of 20%.  
Calculations performed using PASS 14 (Kaysville, UT, [LOCATION_003]).  Allow ing up to 15% attrition, up 
to 68 subj ects , will be needed for the evaluation of this objective performance criterion . 
23.5  Criteria for Termination  
If the upper 95% exact binomial confidence bound is less than the mortality performance 
goal of 20%, then the trial will be considered  a success and  the Tendyne Mitral Valve System 
is deemed  safe.   Enrollment will continue beyond this endpoint  for additional data.  
Additionally, the independent Data Safety Monitoring Board (DSMB) will be monitoring the 
cond uct of the trial. The protocol S ection 21.1  states that the entire study or any individual 
site may be suspended or terminated prematurely by [CONTACT_766874]. Possible reasons for early study 
termination include the discovery of an unexpected, significant, or unacceptable risk to the 
subjects enrolled in the study. For details, refer to protocol S ection 19.6 .  
The role of the DSMB is described in the proto col S ection 19.6 . The DSMB is responsible for 
the study review and to recommend any modification or study termination for any perceived 
safety concern based on clinical judgement, including but not limited to : a higher than 
anticipated rate for any component  of the primary safety endpoint;  device failu res resulting 
in adverse events;  or unexpected SAEs. Possible reasons for early study termination include 
the discovery of an unexpected, significant, or unaccep table risk to the subjects enrolled in 
the study.  
At the conclusion of each DSMB meeting, a recommendation will be made to the sponsor on 
whether to continue, suspend, modify or stop the study.  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 78 of 87   
23.6  Analysis P opulations   
All subjects with a procedure attempt where the Tendyne Mitral Valve System is introduced 
into the body will be included in the analysis  (Intent to Treat) . The portion of subjects that 
have died within 30 days of the procedure attempt will be summarized.  An analysis will also  
be conducted in the implanted patient population (IPP), which includes subjects leaving the 
operating room with study device implanted.  The one -sided 95% exact binomial upper 
confidence bound will be calculated for this 30 -day mortality rate.  If this val ue is less than 
the performance goal of 20%, then we will conclu de that the Tendyne Mitral Valve S ystem is 
safe.  
For adverse event reporting, which includes the primary and secondary safety endpoints, the 
primary analysis will be based on subject counts, n ot event counts.  A subject with more than 
one event will be counted only once toward the event rate based on the total number of 
subjects with adverse events.  An event rate based on event counts will also be presented.   
All CE C adjudicated device, system, and/or procedure related serious AEs will be summarized 
including 95% exact Clopper Pearson confidence interval as the primary endpoint. Unless 
specified otherwise, statistical significance will be declared if the two -sided p -value is < 0.05 . 
23.7 Calculation of S ample Size for Safety  
In addition to gathering of long -term performance of the Tendyne  Mitral Valve  System, 
another goal of this trial is to gather more information on rare adverse events.  While no pass 
or fail endpoint is specified, a certain level of precision can be achieved around rare AEs.  For 
example, for events that occur in 1% of the population, a sample size of 200  subjects will 
provide a 95% confidence interval width of 3.4%  around that estimate .  The following ta ble 
calculates the expected confidence interval width for AEs with a 1% incidence rate.  
Table 6 Sample Size, 95% Confidence Interval  
 
Sample Size   95% Confidence Interval W idth 
with 1% E vent Rate 
150 4.1%  
175 3.7%  
200 3.4%  
225 3.2%  
250 3.0%  
275 2.8%  
300 2.7%  
325 2.6%  
350 2.5%  
375 2.4%  
400 2.3%  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 79 of 87   
A sample size of up to 350 subjects may be enrolled to achieve an estimated confidence 
interval width of 2.5% for events occurring in 1% of the population.  The goal is to achieve at 
least a 4% CI width for events occurring in 1% of the populations, and at least 150 subjects 
will be enrolled.  
23.8  Planned Subgroup Analyses  
Sub-group analyses on performance, effectiveness, and safety endpoints are plan ned. These 
analyses will include certain baseline demographics, disease characteristics, 
echocardiography parameters, and procedural characteristics selected by [CONTACT_766875] a comprehensive understanding of device performance and safety profile.  
23.9  Comparison of Tendyne 1.0 Valve and Tendyne Low Profile (LP)  
Comparisons will be made between the Tendyne 1.[ADDRESS_1051701] of all available data evaluated under ITT principles, referred to 
in International Conference on Harmonization module E9 (Statistical Principles for Clinical 
Trials) as the full analysis set. Consequentl y, data will only be absent from analyses of study 
outcomes in the event that they were not available for collection.  
Tendyne will minimize the incidence of missing data through appropriate management of the 
clinical investigation, proper screening of stud y participants as well as thorough training of 
investigators, monitors and study coordinators. Every effort must be taken by [CONTACT_766876]. Queries wil l be sent to investigators, whenever inconsistent or 
missing data occurs, by [CONTACT_11200], data management personnel or other Sponsor 
designated personnel. Missing data is documented as “ND” (“Not Determined”) on the CRF.  
In general, missing values in  any of the endpoints will not be imputed when summarizing 
these endpoints using descriptive statistics. Patients lost to follow -up will not be excluded 
from further analysis . 
  
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 80 of 87  24 Appendix C 
References  
 
1 Enriquez -Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet.  
2009;373(9672):1382 –94. doi:10.1016/S0140 -6736(09)[ZIP_CODE] -9. 
2 McCarthy KP, Ring L, Rana BS. Anatomy of the mitral valve: understanding the mitral valve 
complex in mitral regurgitation. Eur J Echocardiogr.  2010;11(10):i3 –9. 
doi:10.1093/ejechocard/jeq153.  
3 Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet . 2009;374(9697):1271 –83. 
doi:10.1016/S0140 -6736(09)[ZIP_CODE] -6. 
4 Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart 
disease: The Task Force on the Management of Valvular Heart Disease of the European 
Society of Cardiology . Eur Heart J.  2007;28(2):230 –68. doi:10.1093/eurheartj/ehl428.  
5 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez -Sarano M. Burden of 
valvular heart diseases: a population -based study. Lancet.  2006;368(9540):1005 –11. 
doi:10.1016/S0140 -6736(06)[ZIP_CODE] -8. 
6 Iung B, Baron G, Tornos P, Gohlke -Bärwolf C, Butchart EG, Vahanian A. Valvular heart 
disease in the community: a European experience. Curr Probl Cardiol.  2007;32(11):609 –61. 
doi:10.1016/j.cpcardiol.2007.07.002.  
7 Iung B. A prospective surv ey of patients with valvular heart disease in Europe: The Euro 
Heart Survey on Valvular Heart Disease. Eur Heart J.  2003;24(13):1231 –1243. 
doi:10.1016/S0195 -668X(03)[ZIP_CODE] -X. 
8 Iung B, Baron G, Tornos P, Gohlke -Bärwolf C, Butchart EG, Vahanian A. Valvular h eart 
disease in the community: a European experience. Curr Probl Cardiol.  2007;32(11):609 –61. 
doi:10.1016/j.cpcardiol.2007.07.002.  
9 Carpentier A. Cardiac valve surgery --the “French correction”. J Thorac Cardiovasc Surg.  
1983;86(3):323 –37. 
10 Trichon BH, O’ Connor CM. Secondary mitral and tricuspid regurgitation accompanying 
left ventricular systolic dysfunction: Is it important, and how is it treated? Am Heart J.  
2002;144(3):373 –376. doi:10.1067/mhj.2002.123576.  
11 Avierinos J -F. Natural History of Asymptomatic Mitral Valve Prolapse in the Community. 
Circulation.  2002;106(11):1355 –1361. doi:10.1161/01.CIR.[PHONE_15992].[ZIP_CODE].09.  
12 Bursi F, Enriquez -Sarano M, Nkomo VT, et al. Heart failure and death after myocardial 
infarction in the community: the emerging role of mitral regurgitation. Circulation.  
2005;111(3):295 –301. doi:10.1161/01.CIR.[PHONE_15993].[ZIP_CODE].04.  
13 Grigioni F, Enriquez -Sarano M, Zehr KJ, Bailey KR, Tajik a. J. Ischemic Mitral 
Regurgitation : Long -Term Outcome  and Prognostic Implications With Quantitative Doppler 
Assessment. Circulation.  2001;103(13):1759 –1764. doi:10.1161/01.CIR.103.13.1759.  
14 Pellizzon GG, Grines CL, Cox D a, et al. Importance of mitral regurgitation inpatients 
undergoing percutaneous coronar y intervention for acute myocardial infarction: the 
Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications 
(CADILLAC) trial. J Am Coll Cardiol.  2004;43(8):1368 –74. doi:10.1016/j.jacc.2003.11.046.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 81 of 87   
15 De Servi S, Vaccari L, Assa ndri J, et al. Clinical significance of mitral regurgitation in 
patients with recent myocardial infarction. Eur Heart J.  1988;[ADDRESS_1051702] F:5 –9. 
16 Vassileva CM, Enriquez -Sarano M. No man’s land: ischemic mitral regurgitation 
afterprimary percutaneous coronary intervention. J Thorac Cardiovasc Surg.  
2013;146(1):2 –3. doi:10.1016/j.jtcvs.2013.04.004.  
17 Bonow RO, Carabello B a, Kanu C, et al. ACC/AHA 2006 guidelines for the management of 
patients with valvular heart disease: a report of the American College of Card iology/American 
Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 
Guidelines for the Manage. ; 2006:e84 –231. doi:10.1161/CIRCULATIONAHA.106.176857.  
18 Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart 
disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease 
of the European Society of Cardiology (ESC) and the European Association for Cardio -
Thoracic Surgery (EACTS). Eur J Cardiothorac Surg.  2012;42(4):S1 –44. 
doi:10.1093/ejcts/ezs455.  
19 Himelman RB, Kusumoto F, Oken K, et al. The flail mitral valve: echocardiographic 
findings by [CONTACT_766877] f low mappi[INVESTIGATOR_007]. J Am 
Coll Cardiol.  1991;17(1):272 –9. 
20 Horstkotte D, Loogen F, Kleikamp G, Schulte HD, Trampi[INVESTIGATOR_315079], Bircks W. [Effect of 
prosthetic heart valve replacement on the natural course of isolated mitral and aortic as 
well as multivalvular diseases.  Clinical results in 783 patients up to 8 years following 
implantation of the Björk -Shiley tilting disc prosthesis]. Z Kardiol.  1983;72(9):494 –503.  
21 Muñoz S, Gallardo J, Diaz -Gorrin JR, Medina O. Influence of surgery on the natural history 
of rheumatic mitral and aortic valve disease. Am J Cardiol.  1975;35(2):234 –42. 
[ADDRESS_1051703] Vrain J, Mrosek D, Labovitz AJ. Color Doppler echocardiographic evalu ation 
of patients with a flail mitral leaflet. J Am Coll Cardiol.  1990;16(1):232 –9. 
23 Rapaport E. Natural history of aortic and mitral valve disease. Am J Cardiol.  
1975;35(2):221 –7. 
24 Bach DS, Awais M, Gurm HS, Kohnstamm S. Failure of guideline adherence f or 
intervention in patients with severe mitral regurgitation. J Am Coll Cardiol.  2009;54(9):860 –
5. doi:10.1016/j.jacc.2009.03.079.  
25 Badhwar V, Peterson ED, Jacobs JP, et al. Longitudinal outcome of isolated mitral repair in 
older patients: results from 14 ,604 procedures performed from 1991 to 2007. Ann Thorac 
Surg.  2012;94(6):1870 –7; discussion 1877 –9. doi:10.1016/j.athoracsur.2012.05.105.  
26 Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, 
symptomatic, mitral regurgi tation who are denied surgery? Eur Heart J.  2007;28(11):1358 –
65. doi:10.1093/eurheartj/ehm001.  
27 Toledano K, Rudski LG, Huynh T, Béïque F, Sampalis J, Morin J -F. Mitral regurgitation: 
determinants of referral for cardiac surgery by [CONTACT_766878]. Can J Cardiol.  
2007;23(3):209 –14. 
28 Capomolla S, Febo O, Gnemmi M, et al. Beta -blockade therapy in chronic heart failure: 
diastolic function and mitral regurgitation improvement by [CONTACT_766879]. Am Heart J.  
2000;139(4):596 –608.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ADDRESS_1051704] of carvedilol therapy on 
functional mitral r egurgitation, ventricular remodeling, and contractility in patients with 
heart failure due to left ventricular systolic dysfunction. Transplant Proc.  2002;34(1):177 –8. 
[ADDRESS_1051705] I.  Increased exercise ejection fraction and reversed 
remodeling after long - term treatment with metoprolol in congestive heart failure : a 
randomized , stratified , double -blind , placebo -controlled trial in mild to  moderate heart 
failure due to ischemic or idiopathic dilated cardiomyopathy . Eur J Heart Fail.   2003;5:679 –
691. doi:10.1016/S1388 -9842.  
31 Breithardt O a., Sinha AM, Schwammenthal E, et al. Acute effects of cardiac 
resynchronization therapy on functional mitral regurgitation in advanced systolic heart 
failure. J Am Coll Cardiol.  2003;41(5):765 –770. doi:10.1016/S0735 -1097(02)[ADDRESS_1051706] of cardiac resynchronization 
therapy on left ventricular size and function in chronic heart failure. Circulation.  
2003;107(15):1985 –90. doi:10.11 61/01.CIR.[PHONE_15994].[ZIP_CODE].E9.  
33 Lehmann KG, Francis CK, Dodge HT. Mitral regurgitation in early myocardial infarction. 
Incidence, clinical detection, and prognostic implication s. TIMI Study Group. Ann Intern Med.  
1992;117(1):10 –7. 
[ADDRESS_1051707] -time acute 
myocardial infarction --early and late findings by [CONTACT_45066]. Clin Cardiol.  
1993;16(1):30 –4. 
35 Harris KM, Sundt TM, Aeppli D, Sharma R, Barzilai B. Can late survival of patients with 
moderate ischemic mitral regurgitation be impacted by [CONTACT_766880]? Ann 
Thorac Surg.  2002;74(5):1468 –75. 
36 Lam B -K, Gillinov a M, Black stone EH, et al. Importance of moderate ischemic mitral 
regurgitation. Ann Thorac Surg.  2005;79(2):462 –70; discussion 462 –70. 
doi:10.1016/j.athoracsur.2004.07.040.  
37 Prifti E, Bonacchi M, Frati G, et al. Should mild -to-moderate and moderate ischemic mitral  
regurgitation be corrected in patients with impaired left ventricular function undergoing 
simultaneous coronary revascularization? J Card Surg.  2001;16(6):473 –83. 
[ADDRESS_1051708] of mitral valve regurgitation evaluated by 
[CONTACT_766881] -term outcomes after coronary 
artery by[CONTACT_15806]. Circulation.  2005;112([ADDRESS_1051709]):I293 –8. 
doi:10.1161/CIRCULATIONAHA.104.523472.  
39 Chang B -C, Youn Y -N, Ha J -W, Lim S -H, Hong Y -S, Chung N. Long -term clinical results of 
mitral valvuloplasty using flexible and rigid rings: a prospective and randomized study. J 
Thorac Cardiovasc Surg.  2007;133(4):995 –1003. doi:10.1016/j.jtcvs.2006.10.023.  
40 McGee EC, Gillinov a M, Blackstone EH, et al. Recurrent mitra l regurgitation after 
annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg.  
2004;128(6):916 –24. doi:10.1016/j.jtcvs.2004.07.037.  
41 Spoor MT, Geltz A, Bolling SF. Flexible versus nonflexible mitral valve rings for congestive 
heart failure: differential durability of repair. Circulation.  2006;114([ADDRESS_1051710]):I67 –71. 
doi:10.1161/CIRCULATIONAHA.105.001453.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 83 of 87   
42 Tahta SA, Oury JH, Maxwell JM, Hiro SP, Duran CMG. Outcome after mitral valve repair for 
functional ischemic mitral regurgitati on. J Heart Valve Dis.  2002;11(1):11 –8; discussion 18 –
9. 
43 David TE, Ivanov J, Armstrong S, Christie D, Rakowski H. A comparison of outcomes of 
mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. 
J Thorac Cardiova sc Surg.  2005;130(5):1242 –9. doi:10.1016/j.jtcvs.2005.06.046.  
44 Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate -term outcome of mitral 
reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg.  1998;115(2):381 –6; 
discussion 387 –8. 
45 De Bonis M, Taramasso M, Grimaldi A, et al. The GeoForm annuloplasty ring for the 
surgical treatment of functional mitral regurgitation in advanced dilated cardiomyopathy. 
Eur J Cardiothorac Surg.  2011;40(2):488 –95. doi:10.1016/j.ejcts.2010.11.048.  
[ADDRESS_1051711] Surg.  1989;4(4):286 –90. 
47 Salvador L, Mirone S, Bianchini R, et al. A 20 -year experience with mitral valve repair with 
artificial chordae in 608 patients. J Thorac Cardiovasc Surg.  2008;135(6):1280 –7. 
doi:10.1016/j.jtcvs.2007.12.026.  
48 Alfieri O, Maisano F, De Bonis M, et al. The double -orifice technique in mitral valve re pair: 
a simple solution for complex problems. J Thorac Cardiovasc Surg.  2001;122(4):674 –81. 
doi:10.1067/mtc.2001.117277.  
49 De Bonis M, Lorusso R, Lapenna E, et al. Similar long -term results of mitral valve repair for 
anterior compared with posterior leafle t prolapse. J Thorac Cardiovasc Surg.  
2006;131(2):364 –70. doi:10.1016/j.jtcvs.2005.09.040.  
50 Alfieri O, De Bonis M, Maisano F, La Canna G. Future directions in degenerative mitral 
valve repair. Semin Thorac Cardiovasc Surg.  2007;19(2):127 –32. 
doi:10.1053/j .semtcvs.2007.05.002.  
51 Fann JI, Miller DC, Moore K a, et al. Twenty -year clinical experience with porcine 
bioprostheses. Ann Thorac Surg.  1996;62(5):1301 –11; discussion 1311 –2. 
doi:10.1016/0003 -4975(96)[ZIP_CODE] -7. 
52 Vahanian A, Alfieri O, Andreotti F, et al.  Guidelines on the management of valvular heart 
disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease 
of the European Society of Cardiology (ESC) and the European Association for Cardio -
Thoracic Surgery (EACTS). Eur J Car diothorac Surg.  2012;42(4):S1 –44. 
doi:10.1093/ejcts/ezs455.  
53 O’Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac 
surgery risk models: part 2 --isolated valve surgery. Ann Thorac Surg.  2009;88([ADDRESS_1051712]):S23 –42. doi:10.1016 /j.athoracsur.2009.05.056.  
54 Bonow RO, Carabello B a, Kanu C, et al. ACC/AHA 2006 guidelines for the management of 
patients with valvular heart disease: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 
Guidelines for the Manage. ; 2006:e84 –231. doi:10.1161/CIRCULATIONAHA.106.176857.  
55 Gillinov a M, Wierup PN, Blackstone EH, et al. Is repair preferable to replacement for 
ischemic mitral regurgitatio n? J Thorac Cardiovasc Surg.  2001;122(6):1125 –41. 
doi:10.1067/mtc.2001.116557.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 84 of 87   
56 Gams E, Schad H, Heimisch W, Hagl S, Mendler N, Sebening F. Preservation versus 
severance of the subvalvular apparatus in mitral valve replacement: an experimental study. 
Eur J Cardiothorac Surg.  1990;4(5):250 –5; discussion 255 –6. 
57 Okita Y, Miki S, Ueda Y, Tahata T, Sakai T, Matsuyama K. Mitral valve replacement with 
maintenance of mitral annulopapi[INVESTIGATOR_766824]. J 
Thorac Cardiovasc S urg.  1994;108(1):42 –51. 
58 Okita Y, Miki S, Ueda Y, Tahata T, Sakai T. Left ventricular function after mitral valve 
replacement with or without chordal preservation. J Heart Valve Dis.  1995;[ADDRESS_1051713] 2:S181 –
92; discussion S192 –3. 
59 Solomon NAG, Pranav SK, Nai k D, Sukumaran S. Importance of preservation of chordal 
apparatus in mitral valve replacement. Expert Rev Cardiovasc Ther.  2006;4(2):253 –61. 
doi:10.1586/14779072.4.2.253.  
60 Acker M a., Parides MK, Perrault LP, et al. Mitral -Valve Repair versus Replacement for 
Severe Ischemic Mitral Regurgitation. N Engl J Med.  2013:131118084523001. 
doi:10.1056/NEJMoa1312808.  
61 Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: 
safety and midterm durability in the initial EVEREST (Endov ascular Valve Edge -to-Edge 
REpair Study) cohort. J Am Coll Cardiol.  2009;54(8):686 –94. doi:10.1016/j.jacc.2009.03.077.  
62 Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral 
regurgitation. N Engl J Med.  2011;364(15):1395 –406. do i:10.1056/NEJMoa1009355.  
63 Franzen O, Baldus S, Rudolph V, et al. Acute outcomes of MitraClip therapy for mitral 
regurgitation in high -surgical -risk patients: emphasis on adverse valve morphology and 
severe left ventricular dysfunction. Eur Heart J.  2010;3 1(11):1373 –81. 
doi:10.1093/eurheartj/ehq050.  
64 Franzen O, van der Heyden J, Baldus S, et al. MitraClip® therapy in patients with end -
stage systolic heart failure. Eur J Heart Fail. 2011;13(5):569 –76. doi:10.1093/eurjhf/hfr029.  
65 Mauri L, Foster E, Glower D D, et al. 4 -Year Results of a Randomized Controlled Trial of 
Percutaneous Repair Versus Surgery for Mitral Regurgitation. J Am Coll Cardiol. 
2013;62(4):317 –28. doi:10.1016/j.jacc.2013.04.030.  
66 Paranskaya L, D’Ancona G, Bozdag -Turan I, et al. Early and mid -term outcomes of 
percutaneous mitral valve repair with the MitraClip®: comparative analysis of different 
EuroSCORE strata. EuroIntervention.  2012;8(5):571 –8. doi:10.4244/EIJV8I5A88.  
67 Schilling er W, Hünlich M, Baldus S, et al. Acute outcomes after MitraClip therapy in highly 
aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) 
Registry. EuroIntervention.  2013;9(1):84 –90. doi:10.4244/EIJV9I1A13.  
68 Tamburino C, U ssia GP, Maisano F, et al. Percutaneous mitral valve repair with the 
MitraClip system: acute results from a real world setting. Eur Heart J.  2010;31(11):1382 –9. 
doi:10.1093/eurheartj/ehq051.  
[ADDRESS_1051714], Feldman T, Pedersen WR, et al. Acute and 12 -month r esults with catheter -
based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge -to-Edge Repair) 
High Risk Study. J Am Coll Cardiol.  2012;59(2):130 –9. doi:10.1016/j.jacc.2011.08.067.  
70 Harnek J, Webb JG, Kuck K -H, et al. Transcatheter implan tation of the MONARC coronary 
sinus device for mitral regurgitation: 1 -year results from the EVOLUTION phase I study 
(Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System 
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 85 of 87   
for the Treatment of Mitral R. JACC Cardiovasc Int erv. 2011;4(1):115 –22. 
doi:10.1016/j.jcin.2010.08.027.  
71 Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional 
mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union 
Study. Circulation.  2009 ;120(4):326 –33. doi:10.1161/CIRCULATIONAHA.109.849885.  
72 Maisano, [LOCATION_009]sco; Kuck, Karl -Heinz; Colombo, Anotonio; Nickenig, Georg; Baldus, 
Stephen; Messika -Zeitoun; Vahanian, Alec Percutaneous Mitral Valve Direct Annuloplasty 
with a “Surgical -Like” Ring: R esults from Multicentre First -in-Man Feasibility Trial J Am Coll 
Cardiol.  2015; 65 (10_S):.doi:10.1016/S0735 -1097(15)[ZIP_CODE] -6 
73 Tang G, Lansman S, Cohen M, Spi[INVESTIGATOR_188311] D, Cuomo L, Ahmad H, Dutta T.  Transcatheter 
Aortic Valve Replacement:  Current Developmen ts, Ongoing Issues, Future Outlook.  
Cardiology in Review.  2013; 21(2):55 -76. 
74 Iino K, Boldt J, Lozonschi L, et al. Off-pump transapi[INVESTIGATOR_766825]: 
evaluation after one month. Eur J Cardiothorac Surg.  2012;41(3):512 –7. 
doi:10.1093/ejcts/ezr106.  
75 Ma L, Tozzi P, Huber CH, Taub S, Gerelle G, von Segesser LK. Double -crowned valved 
stents for off -pump mitral valve replacement. Eur J Cardiothorac Surg.  2005;28(2):194 –8; 
discussion 198 –9. doi:10.1016/j.ejcts.2004.12.068.  
[ADDRESS_1051715] the percutaneous replacement of 
atrioventricular valves an experimental study. J Am Coll Cardiol.  2005;46(2):360 –5. 
doi:10.1016/j.jacc.2005.01.063.  
77 Lozonschi L, Quaden R, Edwards NM, Cremer J, Lutter G. Transapi[INVESTIGATOR_766826] d stent 
implantation. Ann Thorac Surg. 2008;86(3):745 –8. doi:10.1016/j.athoracsur.2008.05.039.  
78 Lutter G, Quaden R, Osaki S, et al. Off -pump transapi[INVESTIGATOR_766825]. Eur J 
Cardiothorac Surg.  2009;36(1):124 –8; discussion 128. doi:10.1016/j.ejc ts.2009.02.037.  
79 Lutter G, Quaden R, Iino K, et al. Mitral valved stent implantation. Eur J Cardiothorac Surg.  
2010;38(3):350 –5. doi:10.1016/j.ejcts.2010.02.022.  
80 Lozonschi L, Bombien R, Osaki S, et al. Transapi[INVESTIGATOR_766827]: a 
survival series in swine. J Thorac Cardiovasc Surg.  2010;140(2):422 –426.e1. 
doi:10.1016/j.jtcvs.2009.12.030.  
81 Attmann T, Pokorny S, Lozonschi L, et al. Mitral valved stent implantation: an overview. 
Minim Invasive Ther Allied Technol.  2011;20(2):78 –84. 
doi:1 0.3109/13645706.2011.554559.  
82 Pokorny S, Dai H, Bähr T, Huenges K. Transapi[INVESTIGATOR_766828] : 
comparison between circular and D -shaped design. EuroIntervention.  2013;Nov 25([ePub 
ahead of print]):1 –9. 
83 Gillespie MJ, Minakawa M, Morita M, et al. Sutureless mitral valve replacement: initial 
steps toward a percutaneous procedure. Ann Thorac Surg.  2013;96(2):670 –4. 
doi:10.1016/j.athoracsur.2013.02.065.  
84 Walther T, Falk V, Dewey T, et al. Valve -in-a-valve concept for transcatheter minimally  
invasive repeat xenograft implantation. J Am Coll Cardiol.  2007;50(1):56 –60. 
doi:10.1016/j.jacc.2007.03.030.  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 86 of 87   
85 Kempfert J, Blumenstein JM, Borger M a, et al. Minimally invasive off -pump valve -in-a-
valve implantation: the atrial transcatheter approach for re-operative mitral valve 
replacement. Eur Heart J.  2008;29(19):2382 –7. doi:10.1093/eurheartj/ehn285.  
86 Boudjemline Y, Pi[INVESTIGATOR_159736] E, Borenstein N, Behr L, Bonhoeffer P. New insights in minimally 
invasive valve replacement: description of a cooperative approach  for the off -pump 
replacement of mitral valves. Eur Heart J. 2005;26(19):2013 –7. 
doi:10.1093/eurheartj/ehi307.  
87 Kempfert J, Blumenstein J, Chu MW a, et al. Minimally invasive off -pump valve -in-a-ring 
implantation: the atrial transcatheter approach for re -operative mitral valve replacement 
after failed repair. Eur J Cardiothorac Surg.  2009;35(6):965 –9; discussion 969. 
doi:10.1016/j.ejcts.2009.02.018.  
88 Shuto T, Kondo N, Dori Y, et al. Percutaneous transvenous Melody valve -in-ring procedure 
for mitral valve replacement. J Am Coll Cardiol.  2011;58(24):2475 –80. 
doi:10.1016/j.jacc.2011.09.021.  
89 Kondo N, Shuto T, McGarvey JR, et al. Melody valve -in-ring proc edure for mitral valve 
replacement: feasibility in four annuloplasty types. Ann Thorac Surg.  2012;93(3):783 –8. 
doi:10.1016/j.athoracsur.2011.12.021.  
90 Zou Y, Ferrari E, von Segesser LK. Off -pump transapi[INVESTIGATOR_766826] -in-ring implantation. 
Eur J Cardioth orac Surg. 2013;43(4):849 –55. doi:10.1093/ejcts/ezs407.  
[ADDRESS_1051716] -in-
Human Off -Pump Transcatheter Mitral Valve Replacement. J Am Coll Cardiol . 2014; 7:1077 -
1078.  
92 Moat N, Duncan A, Lindsay A, et al. Transcatheter Mitral Valve Replacement for the 
Treatment of Mitral Regurgitation: In -Hospi[INVESTIGATOR_766829].  J 
Am Coll Cardiol.  2015;65(21):2352 -2353. doi:10.1016/j.jacc.2015.01.066.  
93 Cheung A, Al -Lawati A. T ranscatheter mitral valve -in-valve implantation: current 
experience and review of literature. Curr Opin Cardiol.  2013;28(2):181 –6. 
doi:10.1097/HCO.0b013e32835cee0e.  
94 Stone  G.W. et al.  ‘Clinical trial design principles and endpoint definitions for transcatheter 
mitral valve repair and replacement. Part 1: clinical trial design principles’ : Clinical Trial 
Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair an d 
Replacement: Part  1: Clinical Trial Design Principles Journal of the American College of 
Cardiology , Volume 66, Issue 3, Pages 278 -307 . 
95 Stone  G.W. et al.  ‘Part 2: endpoint definitions’  Clinical Trial Design Principles and Endpoint 
Definitions for Trans catheter Mitral Valve Repair and Replacement: Part 2: Endpoint 
Definitions: A Consensus Document From the Mitral Val ve Academic Research Consortium  
(MVARC). J Am Coll Cardiol.  2015 Jul 21;66(3):308 -21. 
96 Nishimura RA, Otto CM, Bonow RO, et al. 2014. AHA/AC C Guideline for the management of 
patients with valvular heart disease: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation.  
2014;129:e521 –e643 . (For MR Quantification).  
97 Vahanian A  et al., European Society of Cardiology (ESC) and the European Association for 
Cardio -Thoracic Surgery (EACTS) 2017 Joint Task Force on the Manageme nt of Valvular 
Heart Disease . Eur Heart J.  2012;33:2451 –2496.  (For MR Quantification).  
 
Tendyne Holdings, Inc.   CONFIDENTIAL  
CRD_000 Tendyne EFS  
ABT-CIP-[ZIP_CODE] Tendyne EFS CIP Version H  
20 February 2020  Clinical Investigational Protocol  CS-03 Version  H 
 Page 87 of 87   
98 Blanke P, Park JK, Grayburn P, et al. Left ventricular access point determination for a 
coaxial approach to the mitral annular landing zone in transcatheter mitral valve 
replacement.  J. J Cardiovasc Comput Tomogr.  2017 Jul - Aug;11(4):281 -287.  
 
Other  
Chiam PTL, Ruiz CE. Percutaneous Transcatheter Mitral Valve Repair: A Clasification of the 
Technology. JACC Cardiovasc Interv. 2011;4:1 -13. 
de Marchena E, Badiye A, Robalino G, et al. Respective Prevalence of the Different Carpentier 
Classes of Mitral Regurgitation: A Steppi[INVESTIGATOR_766830]. J Card Surg 2011;26:385 -392.  
Delgado V, Tops LF, Schuijf JD, et al. Succesful Deployment of a Transcatheter  Aortic Valve in 
Bicuspid Aortic Stenosis: Role of Imaging With Multislice Computed Tomography. Circ 
Cardiovasc Imaging. 2009;2:e12 -e13.  
Feldman T. Percutaneous Valve Repair and Replacement: Challenges Encountered, 
Challenges Met, Challenges Ahead. Circula tion 2006;113:771 -773.  
Masson JB, Webb J. Percutaneous Treatment of Mitral Regurgitation. Circ Cardiovasc Interv.  
2009;2:140 -146.  
Roy DA, Schaefer U, Guetta V, et al. Transcatheter Aortic Valve Implantation for Pure Severe 
Aortic Valve Regurgitation. J Am Coll Cardiol  2013;61:1577 -1584.  
Webb J, Dvir D. Transcatheter Aortic Valve Replacement for Bioprosthetic Aortic Valve 
Failure: The Valve -in-Valve Procedure. Circulation  2013; 127:[ADDRESS_1051717] acement. J Am Coll Cardiol  
2012;60:483 -492.  
 